{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:43:32Z","timestamp":1790279012798,"version":"4.1.0"},"reference-count":624,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1210\/er.2018-00005","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T18:04:22Z","timestamp":1524161062000},"page":"440-488","source":"Crossref","is-referenced-by-count":161,"title":["Pituitary Diseases and Bone"],"prefix":"10.1210","volume":"39","author":[{"given":"Gherardo","family":"Mazziotti","sequence":"first","affiliation":[{"name":"Endocrine Unit, Carlo Poma Hospital, Mantua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Frara","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology, Universit\u00e0 Vita-Salute San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology, Universit\u00e0 Vita-Salute San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,4,19]]},"reference":[{"issue":"1","key":"2019041123065755900_B1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ecl.2014.10.014","article-title":"Pituitary diseases and bone","volume":"44","author":"Mazziotti","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9","key":"2019041123065755900_B2","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1359\/jbmr.2001.16.9.1583","article-title":"The bone remodeling compartment: a circulatory function for bone lining cells","volume":"16","author":"Parfitt","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"19","key":"2019041123065755900_B3","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMe058080","article-title":"The fate of circulating osteoblasts","volume":"352","author":"Canalis","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"2019041123065755900_B4","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1172\/JCI10413","article-title":"Marrow stromal stem cells","volume":"105","author":"Bianco","year":"2000","journal-title":"J Clin Invest"},{"issue":"3","key":"2019041123065755900_B5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.stem.2012.02.003","article-title":"Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration","volume":"10","author":"Park","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"21","key":"2019041123065755900_B6","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2014the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"2019041123065755900_B7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1210\/er.2002-0023","article-title":"Bone morphogenetic proteins, their antagonists, and the skeleton","volume":"24","author":"Canalis","year":"2003","journal-title":"Endocr Rev"},{"issue":"9","key":"2019041123065755900_B8","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1073\/pnas.0408742102","article-title":"Regulation of osteoblastogenesis and bone mass by Wnt10b","volume":"102","author":"Bennett","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2019041123065755900_B9","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI28551","article-title":"Regulation of bone mass by Wnt signaling","volume":"116","author":"Krishnan","year":"2006","journal-title":"J Clin Invest"},{"issue":"6","key":"2019041123065755900_B10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0092-8674(00)81696-7","article-title":"Smads: transcriptional activators of TGF-\u03b2 responses","volume":"95","author":"Derynck","year":"1998","journal-title":"Cell"},{"issue":"1","key":"2019041123065755900_B11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1359-6101(97)00036-1","article-title":"Signal transduction by bone morphogenetic proteins","volume":"9","author":"Kawabata","year":"1998","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7","key":"2019041123065755900_B12","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1074\/jbc.M102750200","article-title":"The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways","volume":"277","author":"Nohe","year":"2002","journal-title":"J Biol Chem"},{"key":"2019041123065755900_B13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","article-title":"Wnt signaling in osteoblasts and bone diseases","volume":"341","author":"Westendorf","year":"2004","journal-title":"Gene"},{"issue":"1","key":"2019041123065755900_B14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0092-8674(01)00622-5","article-title":"The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation","volume":"108","author":"Nakashima","year":"2002","journal-title":"Cell"},{"issue":"39","key":"2019041123065755900_B15","doi-asserted-by":"crossref","first-page":"33132","DOI":"10.1074\/jbc.M500608200","article-title":"Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression","volume":"280","author":"Gaur","year":"2005","journal-title":"J Biol Chem"},{"issue":"2","key":"2019041123065755900_B16","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/EJE-17-0920","article-title":"Management of endocrine disease: novel anabolic treatments for osteoporosis","volume":"178","author":"Canalis","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2019041123065755900_B17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/er.2016-1002","article-title":"Notch signaling and the skeleton","volume":"37","author":"Zanotti","year":"2016","journal-title":"Endocr Rev"},{"issue":"2","key":"2019041123065755900_B18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"issue":"2","key":"2019041123065755900_B19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2353\/ajpath.2007.060834","article-title":"Osteoclasts: what do they do and how do they do it","volume":"170","author":"Teitelbaum","year":"2007","journal-title":"Am J Pathol"},{"issue":"1","key":"2019041123065755900_B20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2003.10.005","article-title":"IL-6, RANKL, TNF-\u03b1\/IL-1: interrelations in bone resorption pathophysiology","volume":"15","author":"Kwan Tat","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"2019041123065755900_B21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.abb.2008.03.027","article-title":"Osteoclast\u2013osteoblast communication","volume":"473","author":"Matsuo","year":"2008","journal-title":"Arch Biochem Biophys"},{"issue":"3","key":"2019041123065755900_B22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cell.2006.07.015","article-title":"Boning up on ephrin signaling","volume":"126","author":"Mundy","year":"2006","journal-title":"Cell"},{"issue":"4","key":"2019041123065755900_B23","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1182\/blood-2004-12-4975","article-title":"Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis","volume":"106","author":"Han","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2019041123065755900_B24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/er.2012-1026","article-title":"The osteocyte: an endocrine cell ... and more","volume":"34","author":"Dallas","year":"2013","journal-title":"Endocr Rev"},{"issue":"1","key":"2019041123065755900_B25","doi-asserted-by":"crossref","first-page":"e0115897","DOI":"10.1371\/journal.pone.0115897","article-title":"Osteocyte-derived insulin-like growth factor I is not essential for the bone repletion response in mice","volume":"10","author":"Lau","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"2019041123065755900_B26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.abb.2011.12.020","article-title":"Recent advances in our understanding of 1,25-dihydroxyvitamin D3 regulation of intestinal calcium absorption","volume":"523","author":"Christakos","year":"2012","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"2019041123065755900_B27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1152\/physrev.00014.2015","article-title":"Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects","volume":"96","author":"Christakos","year":"2016","journal-title":"Physiol Rev"},{"issue":"3","key":"2019041123065755900_B28","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s00467-004-1767-7","article-title":"Structural organization and biological relevance of oscillatory parathyroid hormone secretion","volume":"20","author":"Schmitt","year":"2005","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2019041123065755900_B29","doi-asserted-by":"crossref","first-page":"14049","DOI":"10.1038\/boneres.2014.49","article-title":"Parathyroid hormone pulsatility: physiological and clinical aspects","volume":"3","author":"Chiavistelli","year":"2015","journal-title":"Bone Res"},{"issue":"1","key":"2019041123065755900_B30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/abbi.2000.1970","article-title":"Regulation of 25-hydroxyvitamin D3 1\u03b1-hydroxylase gene expression by parathyroid hormone and 1,25-dihydroxyvitamin D3","volume":"381","author":"Brenza","year":"2000","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"2019041123065755900_B31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-030212-183727","article-title":"Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism","volume":"75","author":"Hu","year":"2013","journal-title":"Annu Rev Physiol"},{"issue":"6","key":"2019041123065755900_B32","first-page":"690","article-title":"Anabolic actions of parathyroid hormone on bone","volume":"14","author":"Dempster","year":"1993","journal-title":"Endocr Rev"},{"key":"2019041123065755900_B33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bone.2017.06.027","article-title":"Parathyroid hormone inhibits Notch signaling in osteoblasts and osteocytes","volume":"103","author":"Zanotti","year":"2017","journal-title":"Bone"},{"issue":"6","key":"2019041123065755900_B34","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone"},{"issue":"3","key":"2019041123065755900_B35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.cmet.2017.01.001","article-title":"Parathyroid hormone directs bone marrow mesenchymal cell fate","volume":"25","author":"Fan","year":"2017","journal-title":"Cell Metab"},{"issue":"8","key":"2019041123065755900_B36","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1210\/endo.140.8.6887","article-title":"Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation","volume":"140","author":"Lee","year":"1999","journal-title":"Endocrinology"},{"issue":"9","key":"2019041123065755900_B37","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1210\/endo.142.9.8356","article-title":"Catabolic effects of continuous human PTH (1\u201338) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation","volume":"142","author":"Ma","year":"2001","journal-title":"Endocrinology"},{"issue":"2","key":"2019041123065755900_B38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1359\/JBMR.0301226","article-title":"PTH differentially regulates expression of RANKL and OPG","volume":"19","author":"Huang","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019041123065755900_B39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1152\/physrev.00033.2015","article-title":"Estrogens and androgens in skeletal physiology and pathophysiology","volume":"97","author":"Almeida","year":"2017","journal-title":"Physiol Rev"},{"issue":"3","key":"2019041123065755900_B40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2003-0003","article-title":"Androgens and bone","volume":"25","author":"Vanderschueren","year":"2004","journal-title":"Endocr Rev"},{"issue":"12","key":"2019041123065755900_B41","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/jbmr.1713","article-title":"Androgen receptor (AR) in osteocytes is important for the maintenance of male skeletal integrity: evidence from targeted AR disruption in mouse osteocytes","volume":"27","author":"Sinnesael","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2019041123065755900_B42","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1002\/jcb.23297","article-title":"Sex-specific effects of estrogen and androgen on gene expression in human monocyte-derived osteoclasts","volume":"112","author":"Wang","year":"2011","journal-title":"J Cell Biochem"},{"issue":"5","key":"2019041123065755900_B43","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2007.07.025","article-title":"Estrogen prevents bone loss via estrogen receptor \u03b1 and induction of Fas ligand in osteoclasts","volume":"130","author":"Nakamura","year":"2007","journal-title":"Cell"},{"issue":"8","key":"2019041123065755900_B44","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1359\/jbmr.1998.13.8.1243","article-title":"The role of estrogen in the control of rat osteocyte apoptosis","volume":"13","author":"Tomkinson","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"5594","key":"2019041123065755900_B45","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1074935","article-title":"Reversal of bone loss in mice by nongenotropic signaling of sex steroids","volume":"298","author":"Kousteni","year":"2002","journal-title":"Science"},{"issue":"2","key":"2019041123065755900_B46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/er.2015-1106","article-title":"Role of thyroid hormones in skeletal development and bone maintenance","volume":"37","author":"Bassett","year":"2016","journal-title":"Endocr Rev"},{"issue":"1","key":"2019041123065755900_B47","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bone.2008.03.019","article-title":"Iodothyronine deiodinase enzyme activities in bone","volume":"43","author":"Williams","year":"2008","journal-title":"Bone"},{"issue":"16","key":"2019041123065755900_B48","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1073\/pnas.0911346107","article-title":"Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts","volume":"107","author":"Bassett","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019041123065755900_B49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S8756-3282(97)00097-5","article-title":"The expression of thyroid hormone receptors in human bone","volume":"21","author":"Abu","year":"1997","journal-title":"Bone"},{"issue":"7","key":"2019041123065755900_B50","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1210\/me.2002-0296","article-title":"A thyrotoxic skeletal phenotype of advanced bone formation in mice with resistance to thyroid hormone","volume":"17","author":"O\u2019Shea","year":"2003","journal-title":"Mol Endocrinol"},{"issue":"8","key":"2019041123065755900_B51","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1210\/me.2007-0157","article-title":"Thyroid status during skeletal development determines adult bone structure and mineralization","volume":"21","author":"Bassett","year":"2007","journal-title":"Mol Endocrinol"},{"issue":"9","key":"2019041123065755900_B52","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1002\/jbmr.432","article-title":"Thyroid hormone receptor beta mediates thyroid hormone effects on bone remodeling and bone mass","volume":"26","author":"Monfoulet","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019041123065755900_B53","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1210\/jc.2017-01986","article-title":"High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma","volume":"103","author":"Mazziotti","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/acta.0.1110213","article-title":"Triiodothyronine increases responsiveness of cultured rat bone cells to parathyroid hormone","volume":"111","author":"Schmid","year":"1986","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"1","key":"2019041123065755900_B55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/endo.142.1.7905","article-title":"Mutual up-regulation of thyroid hormone and parathyroid hormone receptors in rat osteoblastic osteosarcoma 17\/2.8 cells","volume":"142","author":"Gu","year":"2001","journal-title":"Endocrinology"},{"issue":"4","key":"2019041123065755900_B56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jcb.240500411","article-title":"Glucocorticoids promote development of the osteoblast phenotype by selectively modulating expression of cell growth and differentiation associated genes","volume":"50","author":"Shalhoub","year":"1992","journal-title":"J Cell Biochem"},{"issue":"2","key":"2019041123065755900_B57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4248\/BR201302001","article-title":"Endogenous glucocorticoids and bone","volume":"1","author":"Zhou","year":"2013","journal-title":"Bone Res"},{"issue":"4","key":"2019041123065755900_B58","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1074\/jbc.M702687200","article-title":"Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling","volume":"283","author":"Zhou","year":"2008","journal-title":"J Biol Chem"},{"issue":"2","key":"2019041123065755900_B59","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/en.2003-0655","article-title":"Transgenic expression of 11\u03b2-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone","volume":"145","author":"Sher","year":"2004","journal-title":"Endocrinology"},{"issue":"4","key":"2019041123065755900_B60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","article-title":"Glucocorticoid-induced osteoporosis: an update","volume":"17","author":"Mazziotti","year":"2006","journal-title":"Trends Endocrinol Metab"},{"issue":"2-4","key":"2019041123065755900_B61","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0171-2985(11)80541-3","article-title":"The C\/EBP family of transcription factors","volume":"193","author":"Wedel","year":"1995","journal-title":"Immunobiology"},{"issue":"8","key":"2019041123065755900_B62","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1128\/MCB.16.8.4128","article-title":"Induction of peroxisome proliferator-activated receptor \u03b3 during the conversion of 3T3 fibroblasts into adipocytes is mediated by C\/EBP\u03b2, C\/EBP\u03b4, and glucocorticoids","volume":"16","author":"Wu","year":"1996","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2019041123065755900_B63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bbrc.2005.01.117","article-title":"Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts","volume":"329","author":"Ohnaka","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2019041123065755900_B64","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1074\/jbc.M406294200","article-title":"Glucocorticoids inhibit the transcriptional activity of LEF\/TCF in differentiating osteoblasts in a glycogen synthase kinase-3\u03b2-dependent and -independent manner","volume":"280","author":"Smith","year":"2005","journal-title":"J Biol Chem"},{"issue":"3","key":"2019041123065755900_B65","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1359\/JBMR.0301242","article-title":"Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k","volume":"19","author":"Liu","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2019041123065755900_B66","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/en.2003-0990","article-title":"Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength","volume":"145","author":"O\u2019Brien","year":"2004","journal-title":"Endocrinology"},{"issue":"3","key":"2019041123065755900_B67","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1359\/JBMR.051103","article-title":"Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice","volume":"21","author":"Lane","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2019041123065755900_B68","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos Int"},{"issue":"10","key":"2019041123065755900_B69","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","article-title":"Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"issue":"3","key":"2019041123065755900_B70","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/endo.139.3.5778","article-title":"Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells","volume":"139","author":"Rubin","year":"1998","journal-title":"Endocrinology"},{"issue":"5","key":"2019041123065755900_B71","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/eje.1.02147","article-title":"High-dose glucocorticoids increase serum levels of soluble IL-6 receptor \u03b1 and its ratio to soluble gp130: an additional mechanism for early increased bone resorption","volume":"154","author":"Dovio","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"44","key":"2019041123065755900_B72","doi-asserted-by":"crossref","first-page":"26607","DOI":"10.1074\/jbc.270.44.26607","article-title":"Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms","volume":"270","author":"Delany","year":"1995","journal-title":"J Biol Chem"},{"issue":"5","key":"2019041123065755900_B73","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrendo.2013.5","article-title":"Glucocorticoids and the regulation of growth hormone secretion","volume":"9","author":"Mazziotti","year":"2013","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"2019041123065755900_B74","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/1043-2760(92)90142-N","article-title":"The role of glucocorticoids in the regulation of growth hormone secretion: mechanisms and clinical significance","volume":"3","author":"Giustina","year":"1992","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B75","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1378\/chest.127.2.515","article-title":"Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment","volume":"127","author":"Malerba","year":"2005","journal-title":"Chest"},{"issue":"3","key":"2019041123065755900_B76","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1210\/jcem.85.3.6531","article-title":"Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone","volume":"85","author":"Terzolo","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B77","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1530\/eje.1.01841","article-title":"Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects","volume":"152","author":"Bonadonna","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2019041123065755900_B78","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s12020-016-1146-8","article-title":"Glucocorticoid-induced osteoporosis: pathophysiological role of GH\/IGF-I and PTH\/VITAMIN D axes, treatment options and guidelines","volume":"54","author":"Mazziotti","year":"2016","journal-title":"Endocrine"},{"issue":"2","key":"2019041123065755900_B79","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"issue":"2","key":"2019041123065755900_B80","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12020-016-0900-2","article-title":"The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis","volume":"52","author":"Vasikaran","year":"2016","journal-title":"Endocrine"},{"issue":"4","key":"2019041123065755900_B81","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","article-title":"Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry","volume":"16","author":"Schousboe","year":"2013","journal-title":"J Clin Densitom"},{"issue":"1","key":"2019041123065755900_B82","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11914-017-0346-3","article-title":"Clinical evaluation of bone strength and fracture risk","volume":"15","author":"de Bakker","year":"2017","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"2019041123065755900_B83","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12020-012-9691-2","article-title":"New advances in imaging osteoporosis and its complications","volume":"42","author":"Griffith","year":"2012","journal-title":"Endocrine"},{"issue":"6","key":"2019041123065755900_B84","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S8756-3282(02)00736-6","article-title":"Estimation of distal radius failure load with micro-finite element analysis models based on three-dimensional peripheral quantitative computed tomography images","volume":"30","author":"Pistoia","year":"2002","journal-title":"Bone"},{"issue":"2","key":"2019041123065755900_B85","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12020-014-0280-4","article-title":"Utility of the trabecular bone score (TBS) in secondary osteoporosis","volume":"47","author":"Ulivieri","year":"2014","journal-title":"Endocrine"},{"issue":"9","key":"2019041123065755900_B86","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/jbmr.2603","article-title":"True gold or pyrite: a review of reference point indentation for assessing bone mechanical properties in vivo","volume":"30","author":"Allen","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019041123065755900_B87","doi-asserted-by":"crossref","first-page":"179S","DOI":"10.1016\/8756-3282(95)00499-8","article-title":"Vertebral fracture epidemiology","volume":"18","author":"Wasnich","year":"1996","journal-title":"Bone"},{"issue":"7","key":"2019041123065755900_B88","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.5650110716","article-title":"Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group","volume":"11","author":"Genant","year":"1996","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019041123065755900_B89","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00198-013-2567-3","article-title":"Vertebral fracture assessment (VFA) by lateral DXA scanning may be cost-effective when used as part of fracture liaison services or primary care screening","volume":"25","author":"Clark","year":"2014","journal-title":"Osteoporos Int"},{"issue":"6","key":"2019041123065755900_B90","first-page":"717","article-title":"Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human","volume":"19","author":"Giustina","year":"1998","journal-title":"Endocr Rev"},{"issue":"3","key":"2019041123065755900_B91","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1210\/jcem.85.3.6461","article-title":"Clinical review 112: does serum growth hormone (GH) binding protein reflect human GH receptor function","volume":"85","author":"Amit","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B92","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1677\/joe.0.1700063","article-title":"The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system","volume":"170","author":"Boisclair","year":"2001","journal-title":"J Endocrinol"},{"issue":"6","key":"2019041123065755900_B93","first-page":"761","article-title":"The insulin-like growth factor-binding protein (IGFBP) superfamily","volume":"20","author":"Hwa","year":"1999","journal-title":"Endocr Rev"},{"issue":"5","key":"2019041123065755900_B94","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2007-0036","article-title":"Growth hormone, insulin-like growth factors, and the skeleton","volume":"29","author":"Giustina","year":"2008","journal-title":"Endocr Rev"},{"issue":"26","key":"2019041123065755900_B95","doi-asserted-by":"crossref","first-page":"15353","DOI":"10.1016\/S0021-9258(18)55399-0","article-title":"Cyclic AMP induces insulin-like growth factor I synthesis in osteoblast-enriched cultures","volume":"265","author":"McCarthy","year":"1990","journal-title":"J Biol Chem"},{"issue":"20","key":"2019041123065755900_B96","doi-asserted-by":"crossref","first-page":"9826","DOI":"10.1073\/pnas.89.20.9826","article-title":"Growth hormone induces multiplication of the slowly cycling germinal cells of the rat tibial growth plate","volume":"89","author":"Ohlsson","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019041123065755900_B97","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1172\/JCI113885","article-title":"Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures","volume":"83","author":"Canalis","year":"1989","journal-title":"J Clin Invest"},{"issue":"10","key":"2019041123065755900_B98","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1210\/endo.138.10.5465","article-title":"Osteogenic protein-1 and insulin-like growth factor I synergistically stimulate rat osteoblastic cell differentiation and proliferation","volume":"138","author":"Yeh","year":"1997","journal-title":"Endocrinology"},{"issue":"2","key":"2019041123065755900_B99","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1210\/endo-125-2-825","article-title":"Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones","volume":"125","author":"Ernst","year":"1989","journal-title":"Endocrinology"},{"issue":"8","key":"2019041123065755900_B100","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1210\/mend-5-8-1081","article-title":"Estradiol regulation of insulin-like growth factor-I expression in osteoblastic cells: evidence for transcriptional control","volume":"5","author":"Ernst","year":"1991","journal-title":"Mol Endocrinol"},{"issue":"10","key":"2019041123065755900_B101","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1210\/mend.15.10.0704","article-title":"Glucocorticoid suppression of IGF I transcription in osteoblasts","volume":"15","author":"Delany","year":"2001","journal-title":"Mol Endocrinol"},{"issue":"2","key":"2019041123065755900_B102","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1359\/jbmr.2000.15.2.188","article-title":"Insulin-like growth factor I production is essential for anabolic effects of thyroid hormone in osteoblasts","volume":"15","author":"Huang","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019041123065755900_B103","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/endo.135.1.8013356","article-title":"Changes in insulin-like growth factor-binding protein expression and secretion during the proliferation, differentiation, and mineralization of primary cultures of rat osteoblasts","volume":"135","author":"Birnbaum","year":"1994","journal-title":"Endocrinology"},{"issue":"5","key":"2019041123065755900_B104","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1210\/endo.136.5.7536661","article-title":"Insulin-like growth factor (IGF) I and retinoic acid induce the synthesis of IGF-binding protein 5 in rat osteoblastic cells","volume":"136","author":"Dong","year":"1995","journal-title":"Endocrinology"},{"issue":"18","key":"2019041123065755900_B105","doi-asserted-by":"crossref","first-page":"10771","DOI":"10.1074\/jbc.270.18.10771","article-title":"Skeletal growth factors regulate the synthesis of insulin-like growth factor binding protein-5 in bone cell cultures","volume":"270","author":"Canalis","year":"1995","journal-title":"J Biol Chem"},{"issue":"1","key":"2019041123065755900_B106","first-page":"228","article-title":"Basal and regulated secretion of insulin-like growth factor binding proteins in osteoblast-like cells is cell line specific","volume":"75","author":"Hassager","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B107","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/jcp.1041600119","article-title":"Complex pattern of insulin-like growth factor binding protein expression in primary rat osteoblast enriched cultures: regulation by prostaglandin E2, growth hormone, and the insulin-like growth factors","volume":"160","author":"McCarthy","year":"1994","journal-title":"J Cell Physiol"},{"issue":"1","key":"2019041123065755900_B108","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1210\/endo.134.1.7506203","article-title":"Glucocorticoid regulation of insulin-like growth factor-binding protein expression in normal human osteoblast-like cells","volume":"134","author":"Okazaki","year":"1994","journal-title":"Endocrinology"},{"issue":"1","key":"2019041123065755900_B109","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1210\/endo.134.1.7506211","article-title":"Evidence that human bone cells in culture produce insulin-like growth factor-binding protein-4 and -5 proteases","volume":"134","author":"Kanzaki","year":"1994","journal-title":"Endocrinology"},{"issue":"2-4","key":"2019041123065755900_B110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0955-2235(95)00032-1","article-title":"Insulin-like growth factor binding protein proteolysis in bone cell models","volume":"6","author":"Conover","year":"1995","journal-title":"Prog Growth Factor Res"},{"issue":"20","key":"2019041123065755900_B111","doi-asserted-by":"crossref","first-page":"8083","DOI":"10.1073\/pnas.86.20.8083","article-title":"Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism","volume":"86","author":"Godowski","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019041123065755900_B112","first-page":"279","article-title":"Expression of a human growth hormone (hGH) receptor isoform is predicted by tissue-specific alternative splicing of exon 3 of the hGH receptor gene transcript","volume":"6","author":"Urbanek","year":"1992","journal-title":"Mol Endocrinol"},{"issue":"7","key":"2019041123065755900_B113","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/ng1379","article-title":"A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone","volume":"36","author":"Dos Santos","year":"2004","journal-title":"Nat Genet"},{"issue":"3","key":"2019041123065755900_B114","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1210\/endo-128-3-1459","article-title":"Growth hormone (GH) receptors in clonal osteoblast-like cells mediate a mitogenic response to GH","volume":"128","author":"Barnard","year":"1991","journal-title":"Endocrinology"},{"key":"2019041123065755900_B115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1651-2227.1993.tb12929.x","article-title":"Identification of growth hormone receptors on human growth plate chondrocytes","volume":"82","author":"Werther","year":"1993","journal-title":"Acta Paediatr Suppl"},{"issue":"3","key":"2019041123065755900_B116","first-page":"131","article-title":"Growth hormone stimulates proliferation of normal human bone marrow stromal osteoblast precursor cells in vitro","volume":"4","author":"Kassem","year":"1994","journal-title":"Growth Regul"},{"issue":"12","key":"2019041123065755900_B117","first-page":"3483","article-title":"Expression of functional growth hormone receptors in cultured human osteoblast-like cells","volume":"80","author":"Nilsson","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2019041123065755900_B118","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1210\/endo.137.7.8770888","article-title":"Insulin-like growth factor I and insulin down-regulate growth hormone (GH) receptors in rat osteoblasts: evidence for a peripheral feedback loop regulating GH action","volume":"137","author":"Leung","year":"1996","journal-title":"Endocrinology"},{"issue":"10","key":"2019041123065755900_B119","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1210\/endo.136.10.7545101","article-title":"Insulin-like growth factor binding proteins-2 and -3 stimulate growth hormone receptor binding and mitogenesis in rat osteosarcoma cells","volume":"136","author":"Slootweg","year":"1995","journal-title":"Endocrinology"},{"issue":"4","key":"2019041123065755900_B120","first-page":"238","article-title":"Growth hormone receptor activity is stimulated by insulin-like growth factor binding protein 5 in rat osteosarcoma cells","volume":"6","author":"Slootweg","year":"1996","journal-title":"Growth Regul"},{"issue":"15","key":"2019041123065755900_B121","doi-asserted-by":"crossref","first-page":"9858","DOI":"10.1073\/pnas.152294299","article-title":"Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis","volume":"99","author":"Gent","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2019041123065755900_B122","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11154-007-9025-5","article-title":"Recent advances in growth hormone signaling","volume":"7","author":"Lanning","year":"2006","journal-title":"Rev Endocr Metab Disord"},{"issue":"17","key":"2019041123065755900_B123","doi-asserted-by":"crossref","first-page":"14443","DOI":"10.1074\/jbc.M010021200","article-title":"Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells","volume":"276","author":"Lai","year":"2001","journal-title":"J Biol Chem"},{"issue":"24","key":"2019041123065755900_B124","doi-asserted-by":"crossref","first-page":"21351","DOI":"10.1074\/jbc.M010921200","article-title":"Sustained activation of the extracellular signal-regulated kinase pathway is required for extracellular calcium stimulation of human osteoblast proliferation","volume":"276","author":"Huang","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"2019041123065755900_B125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1359\/jbmr.2002.17.1.101","article-title":"Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells","volume":"17","author":"Xiao","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2019041123065755900_B126","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1172\/JCI200317261","article-title":"Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids","volume":"111","author":"Kousteni","year":"2003","journal-title":"J Clin Invest"},{"issue":"11","key":"2019041123065755900_B127","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1359\/JBMR.040701","article-title":"Growth hormone attenuates the transcriptional activity of Runx2 by facilitating its physical association with Stat3\u03b2","volume":"19","author":"Ziros","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2019041123065755900_B128","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1210\/me.2013-1178","article-title":"IGF-1R modulation of acute GH-induced STAT5 signaling: role of protein tyrosine phosphatase activity","volume":"27","author":"Gan","year":"2013","journal-title":"Mol Endocrinol"},{"issue":"11","key":"2019041123065755900_B129","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1210\/me.2014-1174","article-title":"Human GH receptor-IGF-1 receptor interaction: implications for GH signaling","volume":"28","author":"Gan","year":"2014","journal-title":"Mol Endocrinol"},{"issue":"7","key":"2019041123065755900_B130","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1007\/PL00000744","article-title":"Structure and function of the type 1 insulin-like growth factor receptor","volume":"57","author":"Adams","year":"2000","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"2019041123065755900_B131","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1210\/endo.132.4.8384986","article-title":"IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3\u2032-kinase","volume":"132","author":"Myers","year":"1993","journal-title":"Endocrinology"},{"issue":"11","key":"2019041123065755900_B132","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1210\/en.2003-0350","article-title":"Parallel phosphatidylinositol-3 kinase and p42\/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells","volume":"144","author":"Grey","year":"2003","journal-title":"Endocrinology"},{"issue":"43","key":"2019041123065755900_B133","doi-asserted-by":"crossref","first-page":"31666","DOI":"10.1074\/jbc.M705219200","article-title":"Mode of growth hormone action in osteoblasts","volume":"282","author":"DiGirolamo","year":"2007","journal-title":"J Biol Chem"},{"issue":"10","key":"2019041123065755900_B134","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1210\/en.2002-220428","article-title":"Bone marrow adipocytes: a neglected target tissue for growth hormone","volume":"143","author":"Gevers","year":"2002","journal-title":"Endocrinology"},{"issue":"10","key":"2019041123065755900_B135","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1074\/jbc.M607530200","article-title":"dlk1\/FA1 regulates the function of human bone marrow mesenchymal stem cells by modulating gene expression of pro-inflammatory cytokines and immune response-related factors","volume":"282","author":"Abdallah","year":"2007","journal-title":"J Biol Chem"},{"issue":"7","key":"2019041123065755900_B136","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1210\/en.2007-0171","article-title":"Dlk1\/FA1 is a novel endocrine regulator of bone and fat mass and its serum level is modulated by growth hormone","volume":"148","author":"Abdallah","year":"2007","journal-title":"Endocrinology"},{"issue":"9","key":"2019041123065755900_B137","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1210\/endo.139.9.6211","article-title":"Growth hormone and insulin-like growth factor I induce bone morphogenetic proteins 2 and 4: a mediator role in bone and tooth formation","volume":"139","author":"Li","year":"1998","journal-title":"Endocrinology"},{"issue":"1","key":"2019041123065755900_B138","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00223-002-2149-4","article-title":"Effects of 24 months of growth hormone (GH) treatment on serum carboxylated and undercarboxylated osteocalcin levels in GH-deficient adults","volume":"74","author":"Hubina","year":"2004","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"2019041123065755900_B139","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1210\/jcem.87.6.8549","article-title":"Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in adults with acquired GH deficiency: a double-blind, randomized, placebo-controlled study","volume":"87","author":"Ueland","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B140","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1677\/joe.1.07073","article-title":"Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells","volume":"192","author":"Mrak","year":"2007","journal-title":"J Endocrinol"},{"issue":"1","key":"2019041123065755900_B141","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/en.2015-1690","article-title":"IGF-I and IGFBP-2 stimulate AMPK activation and autophagy, which are required for osteoblast differentiation","volume":"157","author":"Xi","year":"2016","journal-title":"Endocrinology"},{"issue":"7","key":"2019041123065755900_B142","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/nm.2793","article-title":"Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells","volume":"18","author":"Xian","year":"2012","journal-title":"Nat Med"},{"issue":"6","key":"2019041123065755900_B143","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/jcp.25228","article-title":"Mechanical stimulation and IGF-1 enhance mRNA translation rate in osteoblasts via activation of the AKT-mTOR pathway","volume":"231","author":"Bakker","year":"2016","journal-title":"J Cell Physiol"},{"issue":"6","key":"2019041123065755900_B144","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1083\/jcb.201102090","article-title":"Review series: TOR kinase complexes and cell migration","volume":"194","author":"Liu","year":"2011","journal-title":"J Cell Biol"},{"issue":"22","key":"2019041123065755900_B145","doi-asserted-by":"crossref","first-page":"12103","DOI":"10.1073\/pnas.210394297","article-title":"Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of \u03b2-catenin","volume":"97","author":"Playford","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2019041123065755900_B146","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1172\/JCI109908","article-title":"Effect of insulinlike growth factor I on DNA and protein synthesis in cultured rat calvaria","volume":"66","author":"Canalis","year":"1980","journal-title":"J Clin Invest"},{"issue":"4","key":"2019041123065755900_B147","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1210\/endo.136.4.7895645","article-title":"Insulin-like growth factors inhibit interstitial collagenase synthesis in bone cell cultures","volume":"136","author":"Canalis","year":"1995","journal-title":"Endocrinology"},{"issue":"4","key":"2019041123065755900_B148","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1359\/jbmr.1997.12.4.534","article-title":"Identification and characterization of the insulin-like growth factor I receptor in mature rabbit osteoclasts","volume":"12","author":"Hou","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019041123065755900_B149","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1210\/endo.131.3.1505451","article-title":"Insulin-like growth factor-I supports formation and activation of osteoclasts","volume":"131","author":"Mochizuki","year":"1992","journal-title":"Endocrinology"},{"issue":"5","key":"2019041123065755900_B150","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1210\/en.2007-1068","article-title":"Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice","volume":"149","author":"DeMambro","year":"2008","journal-title":"Endocrinology"},{"issue":"11","key":"2019041123065755900_B151","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/jbmr.2282","article-title":"IGFBP-2 directly stimulates osteoblast differentiation","volume":"29","author":"Xi","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2019041123065755900_B152","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/jbmr.2791","article-title":"IRS-1 functions as a molecular scaffold to coordinate IGF-I\/IGFBP-2 signaling during osteoblast differentiation","volume":"31","author":"Xi","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2019041123065755900_B153","first-page":"2813","article-title":"Purification of a colon cancer cell growth inhibitor and its identification as an insulin-like growth factor binding protein","volume":"51","author":"Culouscou","year":"1991","journal-title":"Cancer Res"},{"issue":"2","key":"2019041123065755900_B154","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/joe.0.1610245","article-title":"Different inhibitory actions of IGFBP-1, -2 and -4 on IGF-I effects in vascular smooth muscle cells","volume":"161","author":"Gustafsson","year":"1999","journal-title":"J Endocrinol"},{"issue":"1","key":"2019041123065755900_B155","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/JOE-16-0673","article-title":"IGFBP-4 regulates adult skeletal growth in a sex-specific manner","volume":"233","author":"Maridas","year":"2017","journal-title":"J Endocrinol"},{"issue":"5","key":"2019041123065755900_B156","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1359\/jbmr.2003.18.5.836","article-title":"Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice decreases bone turnover and causes global growth retardation","volume":"18","author":"Zhang","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2019041123065755900_B157","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.bone.2004.08.011","article-title":"Overexpression of insulin-like growth factor binding protein-5 decreases osteoblastic function in vitro","volume":"35","author":"Durant","year":"2004","journal-title":"Bone"},{"issue":"5","key":"2019041123065755900_B158","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1210\/en.2002-220959","article-title":"A novel insulin-like growth factor (IGF)-independent role for IGF binding protein-3 in mesenchymal chondroprogenitor cell apoptosis","volume":"144","author":"Longobardi","year":"2003","journal-title":"Endocrinology"},{"issue":"24","key":"2019041123065755900_B159","doi-asserted-by":"crossref","first-page":"13215","DOI":"10.1073\/pnas.94.24.13215","article-title":"A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor\/binding protein gene (the Laron mouse)","volume":"94","author":"Zhou","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2019041123065755900_B160","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1172\/JCI10753","article-title":"Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5","volume":"106","author":"Sims","year":"2000","journal-title":"J Clin Invest"},{"issue":"11","key":"2019041123065755900_B161","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1359\/jbmr.2002.17.11.1977","article-title":"Effects of liver-derived insulin-like growth factor I on bone metabolism in mice","volume":"17","author":"Sj\u00f6gren","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2019041123065755900_B162","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1359\/jbmr.060610","article-title":"Role of IGF-I signaling in regulating osteoclastogenesis","volume":"21","author":"Wang","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"46","key":"2019041123065755900_B163","doi-asserted-by":"crossref","first-page":"44005","DOI":"10.1074\/jbc.M208265200","article-title":"Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization","volume":"277","author":"Zhang","year":"2002","journal-title":"J Biol Chem"},{"issue":"7","key":"2019041123065755900_B164","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1172\/JCI9017","article-title":"Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover","volume":"105","author":"Ogata","year":"2000","journal-title":"J Clin Invest"},{"issue":"6","key":"2019041123065755900_B165","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1210\/en.2004-1511","article-title":"Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice","volume":"146","author":"Yamaguchi","year":"2005","journal-title":"Endocrinology"},{"issue":"4","key":"2019041123065755900_B166","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1210\/en.2014-1572","article-title":"Excessive growth hormone expression in male GH transgenic mice adversely alters bone architecture and mechanical strength","volume":"156","author":"Lim","year":"2015","journal-title":"Endocrinology"},{"issue":"3","key":"2019041123065755900_B167","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1096-6374(02)00044-8","article-title":"Subcutaneous administration of insulin-like growth factor (IGF)-II\/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis","volume":"12","author":"Conover","year":"2002","journal-title":"Growth Horm IGF Res"},{"issue":"6","key":"2019041123065755900_B168","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1210\/endo.142.6.8192","article-title":"Systemic administration of insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism","volume":"142","author":"Miyakoshi","year":"2001","journal-title":"Endocrinology"},{"issue":"2","key":"2019041123065755900_B169","first-page":"155","article-title":"Potential mechanism of estrogen-mediated decrease in bone formation: estrogen increases production of inhibitory insulin-like growth factor-binding protein-4","volume":"108","author":"Kassem","year":"1996","journal-title":"Proc Assoc Am Physicians"},{"issue":"6","key":"2019041123065755900_B170","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1210\/endo.140.6.6751","article-title":"Transcriptional activation of insulin-like growth factor-binding protein-4 by 17\u03b2-estradiol in MCF-7 cells: role of estrogen receptor-Sp1 complexes","volume":"140","author":"Qin","year":"1999","journal-title":"Endocrinology"},{"issue":"1","key":"2019041123065755900_B171","first-page":"3","article-title":"Insulin-like growth factors and their binding proteins: biological actions","volume":"16","author":"Jones","year":"1995","journal-title":"Endocr Rev"},{"issue":"10","key":"2019041123065755900_B172","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1359\/jbmr.2003.18.10.1834","article-title":"Perturbations in bone formation and resorption in insulin-like growth factor binding protein-3 transgenic mice","volume":"18","author":"Silha","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2019041123065755900_B173","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1359\/jbmr.070306","article-title":"High serum IGFBP-2 is predictive of increased bone turnover in aging men and women","volume":"22","author":"Amin","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2019041123065755900_B174","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion","volume":"80","author":"Freeman","year":"2000","journal-title":"Physiol Rev"},{"issue":"3","key":"2019041123065755900_B175","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/edrv-16-3-354","article-title":"Structural variants of prolactin: occurrence and physiological significance","volume":"16","author":"Sinha","year":"1995","journal-title":"Endocr Rev"},{"issue":"3","key":"2019041123065755900_B176","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1210\/edrv.19.3.0334","article-title":"Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice","volume":"19","author":"Bole-Feysot","year":"1998","journal-title":"Endocr Rev"},{"issue":"1","key":"2019041123065755900_B177","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/bbrc.1996.1800","article-title":"Expression of prolactin receptors in human osteosarcoma cells","volume":"229","author":"Bataille-Simoneau","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"issue":"1-2","key":"2019041123065755900_B178","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11010-010-0674-4","article-title":"Prolactin alters the mRNA expression of osteoblast-derived osteoclastogenic factors in osteoblast-like UMR106 cells","volume":"349","author":"Wongdee","year":"2011","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"2019041123065755900_B179","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.bone.2007.11.008","article-title":"Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor \u03baB ligand\/osteoprotegerin ratio","volume":"42","author":"Seriwatanachai","year":"2008","journal-title":"Bone"},{"issue":"6","key":"2019041123065755900_B180","doi-asserted-by":"crossref","first-page":"E1216","DOI":"10.1152\/ajpendo.2000.279.6.E1216","article-title":"Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat","volume":"279","author":"Coss","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"2019041123065755900_B181","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/jcb.22161","article-title":"Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization","volume":"107","author":"Seriwatanachai","year":"2009","journal-title":"J Cell Biochem"},{"issue":"3","key":"2019041123065755900_B182","doi-asserted-by":"crossref","first-page":"E609","DOI":"10.1152\/ajpendo.00347.2009","article-title":"Two-step stimulation of intestinal Ca2+ absorption during lactation by long-term prolactin exposure and suckling-induced prolactin surge","volume":"297","author":"Charoenphandhu","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"10","key":"2019041123065755900_B183","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1139\/y96-123","article-title":"Effects of acute and long-term administration of prolactin on bone 45Ca uptake, calcium deposit, and calcium resorption in weaned, young, and mature rats","volume":"74","author":"Krishnamra","year":"1996","journal-title":"Can J Physiol Pharmacol"},{"issue":"1","key":"2019041123065755900_B184","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2170\/physiolsci.RP015007","article-title":"High physiological prolactin induced by pituitary transplantation decreases BMD and BMC in the femoral metaphysis, but not in the diaphysis of adult female rats","volume":"58","author":"Thongchote","year":"2008","journal-title":"J Physiol Sci"},{"issue":"1","key":"2019041123065755900_B185","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1210\/endo.140.1.6436","article-title":"Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice","volume":"140","author":"Cl\u00e9ment-Lacroix","year":"1999","journal-title":"Endocrinology"},{"issue":"4","key":"2019041123065755900_B186","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1210\/endo-110-4-1085","article-title":"Divergent effects of prolactin on estrogen and progesterone production by granulosa cells of rat Graafian follicles","volume":"110","author":"Wang","year":"1982","journal-title":"Endocrinology"},{"issue":"2","key":"2019041123065755900_B187","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0303-7207(80)90077-5","article-title":"Prolactin inhibition of estrogen production by cultured rat granulosa cells","volume":"20","author":"Wang","year":"1980","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"2019041123065755900_B188","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0026-0495(89)90071-1","article-title":"Hypogonadism does not mediate urinary calcium loss in pituitary-grafted rats","volume":"38","author":"Adler","year":"1989","journal-title":"Metabolism"},{"issue":"10","key":"2019041123065755900_B189","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1139\/y00-040","article-title":"Changes in the regulation of calcium metabolism and bone calcium content during growth in the absence of endogenous prolactin and during hyperprolactinemia: a longitudinal study in male and female Wistar rats","volume":"78","author":"Piyabhan","year":"2000","journal-title":"Can J Physiol Pharmacol"},{"issue":"11","key":"2019041123065755900_B190","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1177\/153537020523001108","article-title":"Long-term prolactin exposure differentially stimulated the transcellular and solvent drag-induced calcium transport in the duodenum of ovariectomized rats","volume":"230","author":"Tudpor","year":"2005","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"2019041123065755900_B191","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1210\/edrv.20.1.0355","article-title":"Modulation of gonadotropin levels by peptides acting at the anterior pituitary gland","volume":"20","author":"Evans","year":"1999","journal-title":"Endocr Rev"},{"issue":"5","key":"2019041123065755900_B192","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2014-1003","article-title":"Inhibin at 90: from discovery to clinical application, a historical review","volume":"35","author":"Makanji","year":"2014","journal-title":"Endocr Rev"},{"issue":"6","key":"2019041123065755900_B193","first-page":"739","article-title":"The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology","volume":"18","author":"Simoni","year":"1997","journal-title":"Endocr Rev"},{"issue":"8","key":"2019041123065755900_B194","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.tem.2005.05.011","article-title":"Genetic complexity of FSH receptor function","volume":"16","author":"Gromoll","year":"2005","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"2019041123065755900_B195","first-page":"3365","article-title":"Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype","volume":"85","author":"Perez Mayorga","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B196","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0015-0282(03)00795-7","article-title":"Role of follicle-stimulating hormone receptor Ser680Asn polymorphism in the efficacy of follicle-stimulating hormone","volume":"80","author":"de Castro","year":"2003","journal-title":"Fertil Steril"},{"issue":"1","key":"2019041123065755900_B197","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbrc.2010.02.112","article-title":"FSH-receptor isoforms and FSH-dependent gene transcription in human monocytes and osteoclasts","volume":"394","author":"Robinson","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2019041123065755900_B198","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cell.2006.01.051","article-title":"FSH directly regulates bone mass","volume":"125","author":"Sun","year":"2006","journal-title":"Cell"},{"issue":"2","key":"2019041123065755900_B199","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cyto.2010.11.011","article-title":"Follicle-stimulating hormone promotes RANK expression on human monocytes","volume":"53","author":"Cannon","year":"2011","journal-title":"Cytokine"},{"issue":"4","key":"2019041123065755900_B200","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1210\/jc.2005-1836","article-title":"Hormone predictors of bone mineral density changes during the menopausal transition","volume":"91","author":"Sowers","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B201","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbrc.2010.02.113","article-title":"Further evidence for direct pro-resorptive actions of FSH","volume":"394","author":"Sun","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"40","key":"2019041123065755900_B202","doi-asserted-by":"crossref","first-page":"14925","DOI":"10.1073\/pnas.0606805103","article-title":"Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation","volume":"103","author":"Iqbal","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019041123065755900_B203","doi-asserted-by":"crossref","first-page":"R790","DOI":"10.1152\/ajpregu.00728.2009","article-title":"Follicle-stimulating hormone, interleukin-1, and bone density in adult women","volume":"298","author":"Cannon","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"2019041123065755900_B204","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12020-012-9626-y","article-title":"Further evidence that FSH causes bone loss independently of low estrogen","volume":"41","author":"Iqbal","year":"2012","journal-title":"Endocrine"},{"issue":"5","key":"2019041123065755900_B205","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/8756-3282(96)00045-2","article-title":"Ovariectomy-induced high turnover in cortical bone is dependent on pituitary hormone in rats","volume":"18","author":"Yeh","year":"1996","journal-title":"Bone"},{"issue":"4 Pt 1","key":"2019041123065755900_B206","first-page":"E734","article-title":"Effects of estrogen and growth hormone on skeleton in the ovariectomized rat with hypophysectomy","volume":"273","author":"Yeh","year":"1997","journal-title":"Am J Physiol"},{"issue":"36","key":"2019041123065755900_B207","doi-asserted-by":"crossref","first-page":"14574","DOI":"10.1073\/pnas.1212806109","article-title":"Blocking antibody to the \u03b2-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis","volume":"109","author":"Zhu","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019041123065755900_B208","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2012.04.104","article-title":"Blocking FSH action attenuates osteoclastogenesis","volume":"422","author":"Zhu","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"52","key":"2019041123065755900_B209","doi-asserted-by":"crossref","first-page":"22629","DOI":"10.1073\/pnas.1012141108","article-title":"Follicle-stimulating hormone increases bone mass in female mice","volume":"107","author":"Allan","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2019041123065755900_B210","first-page":"3366","article-title":"Bone turnover markers and bone density across the menopausal transition","volume":"81","author":"Ebeling","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2019041123065755900_B211","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1210\/jc.2008-0482","article-title":"Follicle stimulating hormone and its rate of change in defining menopause transition stages","volume":"93","author":"Sowers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B212","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00198-002-1329-4","article-title":"Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN","volume":"14","author":"Sowers","year":"2003","journal-title":"Osteoporos Int"},{"issue":"2","key":"2019041123065755900_B213","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00198-009-0943-9","article-title":"Age-related changes in biochemical markers of bone turnover and gonadotropin levels and their relationship among Chinese adult women","volume":"21","author":"Wu","year":"2010","journal-title":"Osteoporos Int"},{"issue":"4","key":"2019041123065755900_B214","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11914-010-0028-x","article-title":"The role of FSH and TSH in bone loss and its clinical relevance","volume":"8","author":"Agrawal","year":"2010","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"2019041123065755900_B215","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00198-002-1307-x","article-title":"The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN","volume":"14","author":"Sowers","year":"2003","journal-title":"Osteoporos Int"},{"issue":"5","key":"2019041123065755900_B216","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1210\/jc.2009-0659","article-title":"Amount of bone loss in relation to time around the final menstrual period and follicle-stimulating hormone staging of the transmenopause","volume":"95","author":"Sowers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B217","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.maturitas.2011.01.010","article-title":"Bone loss during menopausal transition among southern Chinese women","volume":"69","author":"Cheung","year":"2011","journal-title":"Maturitas"},{"issue":"1","key":"2019041123065755900_B218","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1530\/EJE-10-0043","article-title":"FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women","volume":"163","author":"Rendina","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2019041123065755900_B219","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1210\/jc.2010-1103","article-title":"Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women","volume":"95","author":"Drake","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B220","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1210\/jc.2012-2778","article-title":"Effects of recombinant follicle-stimulating hormone on bone turnover markers in infertile women undergoing in vitro fertilization procedure","volume":"98","author":"Omodei","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B221","doi-asserted-by":"crossref","first-page":"744","DOI":"10.4049\/jimmunol.142.3.744","article-title":"Thyrotropin: an endogenous regulator of the in vitro immune response","volume":"142","author":"Kruger","year":"1989","journal-title":"J Immunol"},{"issue":"1","key":"2019041123065755900_B222","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/gene.2008.69","article-title":"Bone marrow cells produce a novel TSH\u03b2 splice variant that is upregulated in the thyroid following systemic virus infection","volume":"10","author":"Vincent","year":"2009","journal-title":"Genes Immun"},{"issue":"12","key":"2019041123065755900_B223","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1210\/en.2012-2234","article-title":"Thyroid and bone: macrophage-derived TSH-\u03b2 splice variant increases murine osteoblastogenesis","volume":"154","author":"Baliram","year":"2013","journal-title":"Endocrinology"},{"issue":"9","key":"2019041123065755900_B224","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1210\/en.2015-1974","article-title":"T3 regulates a human macrophage-derived TSH-\u03b2 splice variant: implications for human bone biology","volume":"157","author":"Baliram","year":"2016","journal-title":"Endocrinology"},{"issue":"2","key":"2019041123065755900_B225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/er.2008-0044","article-title":"Thyrotropin and homologous glycoprotein hormone receptors: structural and functional aspects of extracellular signaling mechanisms","volume":"30","author":"Kleinau","year":"2009","journal-title":"Endocr Rev"},{"issue":"5","key":"2019041123065755900_B226","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1530\/eje.1.02279","article-title":"Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases","volume":"155","author":"Peeters","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2019041123065755900_B227","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/thy.1994.4.147","article-title":"Polymorphism of a variant human thyrotropin receptor (hTSHR) gene","volume":"4","author":"Sunthornthepvarakul","year":"1994","journal-title":"Thyroid"},{"issue":"2","key":"2019041123065755900_B228","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0303-7207(95)03562-L","article-title":"Functional analysis of a variant of the thyrotropin receptor gene in a family with Graves\u2019 disease","volume":"111","author":"Gustavsson","year":"1995","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"2019041123065755900_B229","first-page":"3328","article-title":"Germline polymorphism of codon 727 of human thyroid-stimulating hormone receptor is associated with toxic multinodular goiter","volume":"84","author":"Gabriel","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019041123065755900_B230","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1210\/jc.2002-021592","article-title":"Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects","volume":"88","author":"Peeters","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B231","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ecl.2009.01.006","article-title":"The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling","volume":"38","author":"Latif","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"2019041123065755900_B232","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1096\/fj.11-188961","article-title":"Occupancy of both sites on the thyrotropin (TSH) receptor dimer is necessary for phosphoinositide signaling","volume":"25","author":"Allen","year":"2011","journal-title":"FASEB J"},{"issue":"2","key":"2019041123065755900_B233","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/mol.111.072157","article-title":"Thyrotropin receptor stimulates internalization-independent persistent phosphoinositide signaling","volume":"80","author":"Boutin","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"8","key":"2019041123065755900_B234","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1096\/fj.14-251124","article-title":"\u03b2-Arrestin-1 mediates thyrotropin-enhanced osteoblast differentiation","volume":"28","author":"Boutin","year":"2014","journal-title":"FASEB J"},{"issue":"1","key":"2019041123065755900_B235","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.physiol.69.022405.154749","article-title":"\u03b2-Arrestins and cell signaling","volume":"69","author":"DeWire","year":"2007","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"2019041123065755900_B236","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1172\/JCI0216234","article-title":"The TSH receptor reveals itself","volume":"110","author":"Davies","year":"2002","journal-title":"J Clin Invest"},{"issue":"6-7","key":"2019041123065755900_B237","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/08916930310001603019","article-title":"Physiological relevance of thyroid stimulating hormone and thyroid stimulating hormone receptor in tissues other than the thyroid","volume":"36","author":"Klein","year":"2003","journal-title":"Autoimmunity"},{"issue":"10","key":"2019041123065755900_B238","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1210\/jc.2003-030789","article-title":"Recombinant human thyrotropin reduces serum vascular endothelial growth factor levels in patients monitored for thyroid carcinoma even in the absence of thyroid tissue","volume":"88","author":"Sorvillo","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019041123065755900_B239","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/thy.2006.16.531","article-title":"Recombinant human thyrotropin stimulates thyroid angiogenesis in vivo","volume":"16","author":"Klein","year":"2006","journal-title":"Thyroid"},{"issue":"6","key":"2019041123065755900_B240","doi-asserted-by":"crossref","first-page":"E1140","DOI":"10.1152\/ajpendo.00516.2005","article-title":"Interleukin-6 release from human abdominal adipose cells is regulated by thyroid-stimulating hormone: effect of adipocyte differentiation and anatomic depot","volume":"290","author":"Antunes","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B241","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0092-8674(03)00771-2","article-title":"TSH is a negative regulator of skeletal remodeling","volume":"115","author":"Abe","year":"2003","journal-title":"Cell"},{"key":"2019041123065755900_B242","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fendo.2017.00252","article-title":"Expanding the role of thyroid-stimulating hormone in skeletal physiology","volume":"8","author":"Baliram","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2019041123065755900_B243","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/thy.2010.0457","article-title":"The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis","volume":"21","author":"Ma","year":"2011","journal-title":"Thyroid"},{"issue":"11","key":"2019041123065755900_B244","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1073\/pnas.0712395105","article-title":"Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss","volume":"105","author":"Sun","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"2019041123065755900_B245","doi-asserted-by":"crossref","first-page":"15776","DOI":"10.1073\/pnas.242322099","article-title":"Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice","volume":"99","author":"Marians","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"34","key":"2019041123065755900_B246","doi-asserted-by":"crossref","first-page":"12849","DOI":"10.1073\/pnas.0600427103","article-title":"TNF\u03b1 mediates the skeletal effects of thyroid-stimulating hormone","volume":"103","author":"Hase","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"39","key":"2019041123065755900_B247","doi-asserted-by":"crossref","first-page":"16277","DOI":"10.1073\/pnas.1110286108","article-title":"Thyroid-stimulating hormone induces a Wnt-dependent, feed-forward loop for osteoblastogenesis in embryonic stem cell cultures","volume":"108","author":"Baliram","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"2019041123065755900_B248","doi-asserted-by":"crossref","first-page":"9891","DOI":"10.1073\/pnas.1308336110","article-title":"Genetic confirmation for a central role for TNF\u03b1 in the direct action of thyroid stimulating hormone on the skeleton [published correction appears in Proc Natl Acad Sci USA 2013;110(3):12498]","volume":"110","author":"Sun","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1\u20132","key":"2019041123065755900_B249","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11010-012-1345-4","article-title":"Regulation of insulin-like growth factors and their binding proteins by thyroid stimulating hormone in human osteoblast-like (SaOS2) cells","volume":"368","author":"Ramajayam","year":"2012","journal-title":"Mol Cell Biochem"},{"issue":"5","key":"2019041123065755900_B250","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1210\/en.2015-2040","article-title":"Multiple transduction pathways mediate thyrotropin receptor signaling in preosteoblast-like cells","volume":"157","author":"Boutin","year":"2016","journal-title":"Endocrinology"},{"issue":"1","key":"2019041123065755900_B251","doi-asserted-by":"crossref","first-page":"1ra1","DOI":"10.1126\/scitranslmed.3000071","article-title":"A \u03b2-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation","volume":"1","author":"Gesty-Palmer","year":"2009","journal-title":"Sci Transl Med"},{"issue":"30","key":"2019041123065755900_B252","doi-asserted-by":"crossref","first-page":"12471","DOI":"10.1073\/pnas.0904506106","article-title":"Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice","volume":"106","author":"Neumann","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019041123065755900_B253","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1124\/jpet.117.244095","article-title":"Discovery of a positive allosteric modulator of the thyrotropin receptor: potentiation of thyrotropin-mediated preosteoblast differentiation in vitro","volume":"364","author":"Neumann","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"2019041123065755900_B254","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jbiomech.2014.02.015","article-title":"Thyroid-stimulating hormone maintains bone mass and strength by suppressing osteoclast differentiation","volume":"47","author":"Zhang","year":"2014","journal-title":"J Biomech"},{"issue":"10","key":"2019041123065755900_B255","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1172\/JCI63948","article-title":"Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling","volume":"122","author":"Baliram","year":"2012","journal-title":"J Clin Invest"},{"issue":"6","key":"2019041123065755900_B256","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.070302","article-title":"Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats","volume":"22","author":"Sampath","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019041123065755900_B257","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1359\/JBMR.041126","article-title":"Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma","volume":"20","author":"Mazziotti","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019041123065755900_B258","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00774-009-0098-y","article-title":"The effects of recombinant human TSH on bone turnover in patients after thyroidectomy","volume":"28","author":"Karga","year":"2010","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"2019041123065755900_B259","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/thy.2007.0166","article-title":"The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels","volume":"18","author":"Martini","year":"2008","journal-title":"Thyroid"},{"issue":"4","key":"2019041123065755900_B260","doi-asserted-by":"crossref","first-page":"304","DOI":"10.14310\/horm.2002.1111026","article-title":"Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-\u03baB ligand in patients under evaluation for differentiated thyroid carcinoma","volume":"6","author":"Giusti","year":"2007","journal-title":"Hormones (Athens)"},{"issue":"1","key":"2019041123065755900_B261","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2265.2005.02422.x","article-title":"Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women","volume":"64","author":"Kim","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2019041123065755900_B262","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bone.2006.12.001","article-title":"The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women","volume":"40","author":"Morris","year":"2007","journal-title":"Bone"},{"issue":"8","key":"2019041123065755900_B263","doi-asserted-by":"crossref","first-page":"e0136283","DOI":"10.1371\/journal.pone.0136283","article-title":"Risk factors of bone mass loss at the lumbar spine: a longitudinal study in healthy Korean pre- and perimenopausal women older than 40 years","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"2019041123065755900_B264","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00198-014-2906-z","article-title":"A cross-sectional study to examine the correlation between serum TSH levels and the osteoporosis of the lumbar spine in healthy women with normal thyroid function","volume":"26","author":"Noh","year":"2015","journal-title":"Osteoporos Int"},{"issue":"6","key":"2019041123065755900_B265","doi-asserted-by":"crossref","first-page":"734","DOI":"10.14336\/AD.2016.0325","article-title":"Low normal TSH levels are associated with impaired BMD and hip geometry in the elderly","volume":"7","author":"Lee","year":"2016","journal-title":"Aging Dis"},{"issue":"3","key":"2019041123065755900_B266","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2265.2010.03818.x","article-title":"The association between serum thyrotropin (TSH) levels and bone mineral density in healthy euthyroid men","volume":"73","author":"Kim","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2019041123065755900_B267","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7150\/ijms.5870","article-title":"Thyroid-stimulating hormone is significantly associated with bone health status in men","volume":"10","author":"Chin","year":"2013","journal-title":"Int J Med Sci"},{"issue":"8","key":"2019041123065755900_B268","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1210\/jc.2013-2474","article-title":"Thyrotropin levels within the lower normal range are associated with an increased risk of hip fractures in euthyroid women, but not men, over the age of 65 years","volume":"99","author":"Leader","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2019041123065755900_B269","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1210\/jc.2017-00294","article-title":"Thyroid function tests in the reference range and fracture: individual participant analysis of prospective cohorts","volume":"102","author":"Aubert","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B270","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bone.2009.10.031","article-title":"Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density","volume":"46","author":"Mazziotti","year":"2010","journal-title":"Bone"},{"issue":"2","key":"2019041123065755900_B271","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2265.2007.03016.x","article-title":"Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the Rotterdam Study","volume":"68","author":"van der Deure","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2019041123065755900_B272","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/EJE-08-0038","article-title":"Thyroid hormone independent associations between serum TSH levels and indicators of bone turnover in cured patients with differentiated thyroid carcinoma","volume":"159","author":"Heemstra","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2019041123065755900_B273","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1007\/BF03349164","article-title":"Diagnosis and treatment of acromegaly complications","volume":"26","author":"Giustina","year":"2003","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2019041123065755900_B274","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11102-012-0420-x","article-title":"A consensus on the diagnosis and treatment of acromegaly complications","volume":"16","author":"Melmed","year":"2013","journal-title":"Pituitary"},{"issue":"1","key":"2019041123065755900_B275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11102-016-0758-6","article-title":"Acromegalic osteopathy","volume":"20","author":"Mazziotti","year":"2017","journal-title":"Pituitary"},{"issue":"3","key":"2019041123065755900_B276","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0009-8981(79)90285-7","article-title":"Bone isoenzyme of serum alkaline phosphatase in acromegaly","volume":"93","author":"Stepan","year":"1979","journal-title":"Clin Chim Acta"},{"issue":"1","key":"2019041123065755900_B277","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000180625","article-title":"Normal calcitonin secretion in acromegaly","volume":"25","author":"Tabolli","year":"1987","journal-title":"Horm Res"},{"issue":"1","key":"2019041123065755900_B278","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/BF02555167","article-title":"Correlation among plasma osteocalcin, growth hormone, and somatomedin C in acromegaly","volume":"43","author":"de la Piedra","year":"1988","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2019041123065755900_B279","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2265.2001.01280.x","article-title":"Bone metabolism and body composition in Japanese patients with active acromegaly","volume":"55","author":"Kaji","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2019041123065755900_B280","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jbmr.5650080410","article-title":"Bone mineral density and parameters of bone metabolism in patients with acromegaly","volume":"8","author":"Kotzmann","year":"1993","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2019041123065755900_B281","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00571329","article-title":"Serum bone Gla protein as a marker of bone turnover in acromegaly","volume":"52","author":"Marazuela","year":"1993","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2019041123065755900_B282","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-2007-1001672","article-title":"Biochemical markers of bone and collagen turnover in acromegaly or Cushing\u2019s syndrome","volume":"26","author":"Piovesan","year":"1994","journal-title":"Horm Metab Res"},{"issue":"8","key":"2019041123065755900_B283","first-page":"377","article-title":"Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly","volume":"1","author":"Jockenh\u00f6vel","year":"1996","journal-title":"Eur J Med Res"},{"issue":"8","key":"2019041123065755900_B284","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/BF03347998","article-title":"Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations","volume":"20","author":"Legovini","year":"1997","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"2019041123065755900_B285","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1359\/jbmr.1997.12.10.1729","article-title":"Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients","volume":"12","author":"Scillitani","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2019041123065755900_B286","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1530\/eje.0.1450685","article-title":"Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis","volume":"145","author":"Ueland","year":"2001","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2019041123065755900_B287","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s001980200009","article-title":"Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone","volume":"13","author":"Minisola","year":"2002","journal-title":"Osteoporos Int"},{"issue":"12","key":"2019041123065755900_B288","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1210\/jc.2003-030772","article-title":"Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal","volume":"88","author":"Parkinson","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B289","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00774-005-0649-9","article-title":"Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function","volume":"24","author":"Bolanowski","year":"2006","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"2019041123065755900_B290","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1210\/jc.2005-1602","article-title":"Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity","volume":"91","author":"White","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B291","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1210\/jc.2014-2937","article-title":"Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis","volume":"100","author":"Mazziotti","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B292","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/er.2013-1071","article-title":"Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications","volume":"35","author":"Kamenick\u00fd","year":"2014","journal-title":"Endocr Rev"},{"issue":"4","key":"2019041123065755900_B293","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s11102-013-0514-0","article-title":"The effect of somatostatin analogs on vitamin D and calcium concentrations in patients with acromegaly","volume":"17","author":"Ajmal","year":"2014","journal-title":"Pituitary"},{"key":"2019041123065755900_B294","first-page":"89","article-title":"Patients with active acromegaly are at high risk of 25(OH)D deficiency","volume":"6","author":"Halupczok-\u017by\u0142a","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2019041123065755900_B295","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12020-016-0890-0","article-title":"Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy","volume":"52","author":"Mazziotti","year":"2016","journal-title":"Endocrine"},{"issue":"2","key":"2019041123065755900_B296","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12020-015-0789-1","article-title":"Vitamin D-binding protein and free vitamin D concentrations in acromegaly","volume":"52","author":"Altinova","year":"2016","journal-title":"Endocrine"},{"issue":"6","key":"2019041123065755900_B297","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.metabol.2006.01.009","article-title":"Active acromegaly enhances spontaneous parathyroid hormone pulsatility","volume":"55","author":"Mazziotti","year":"2006","journal-title":"Metabolism"},{"issue":"7","key":"2019041123065755900_B298","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1210\/jc.2016-3693","article-title":"Calcium and bone turnover markers in acromegaly: a prospective, controlled study","volume":"102","author":"Constantin","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B299","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000375450","article-title":"Bone and joint disorders in acromegaly","volume":"103","author":"Claessen","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"5","key":"2019041123065755900_B300","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/eje.1.02285","article-title":"Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients","volume":"155","author":"Ueland","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2019041123065755900_B301","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7326\/0003-4819-111-7-567","article-title":"Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism","volume":"111","author":"Diamond","year":"1989","journal-title":"Ann Intern Med"},{"issue":"1","key":"2019041123065755900_B302","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1359\/JBMR.050603","article-title":"Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women","volume":"20","author":"Bonadonna","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2019041123065755900_B303","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1210\/jc.2008-0791","article-title":"Prevalence of vertebral fractures in men with acromegaly","volume":"93","author":"Mazziotti","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2019041123065755900_B304","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1210\/jc.2013-1460","article-title":"Vertebral fractures in patients with acromegaly: a 3-year prospective study","volume":"98","author":"Mazziotti","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2019041123065755900_B305","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/BF03350799","article-title":"Bone mineral density and circulating cytokines in patients with acromegaly","volume":"21","author":"Longobardi","year":"1998","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"2019041123065755900_B306","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1076-6332(00)80573-5","article-title":"Axial bone mineral density in patients with acromegaly","volume":"7","author":"Bolanowski","year":"2000","journal-title":"Acad Radiol"},{"issue":"2","key":"2019041123065755900_B307","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s007740300015","article-title":"Various risks of osteoporosis in patients with pituitary adenomas","volume":"21","author":"Matsuyama","year":"2003","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"2019041123065755900_B308","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1210\/jc.2009-0474","article-title":"A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly","volume":"94","author":"Sucunza","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B309","first-page":"37","article-title":"Prevalence of osteoporosis and vertebral fractures in acromegalic patients","volume":"8","author":"Padova","year":"2011","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"1","key":"2019041123065755900_B310","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1365-2265.1998.00349.x","article-title":"Gonadal status is an important determinant of bone density in acromegaly","volume":"48","author":"Lesse","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2019041123065755900_B311","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-2004-820913","article-title":"Factors associated with bone metabolism in acromegalic patients: hypogonadism and female gender","volume":"112","author":"T\u00fct\u00fcnc\u00fc","year":"2004","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"2019041123065755900_B312","first-page":"621","article-title":"In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender","volume":"28","author":"Zgliczynski","year":"2007","journal-title":"Neuroendocrinol Lett"},{"issue":"2","key":"2019041123065755900_B313","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.0300-0664.2001.01464.x","article-title":"Fracture risk is increased in patients with GH deficiency or untreated prolactinomas\u2014a case-control study","volume":"56","author":"Vestergaard","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2019041123065755900_B314","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1046\/j.1365-2362.2002.00944.x","article-title":"Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly","volume":"32","author":"Ueland","year":"2002","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"2019041123065755900_B315","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-003-1531-z","article-title":"Fracture risk is decreased in acromegaly\u2014a potential beneficial effect of growth hormone","volume":"15","author":"Vestergaard","year":"2004","journal-title":"Osteoporos Int"},{"issue":"3","key":"2019041123065755900_B316","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2265.2008.03322.x","article-title":"Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study","volume":"70","author":"Battista","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2019041123065755900_B317","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1530\/EJE-10-1005","article-title":"High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly","volume":"164","author":"Wassenaar","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2019041123065755900_B318","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12020-011-9486-x","article-title":"Influence of diabetes mellitus on vertebral fractures in men with acromegaly","volume":"40","author":"Mazziotti","year":"2011","journal-title":"Endocrine"},{"issue":"2","key":"2019041123065755900_B319","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jocd.2012.06.002","article-title":"Vertebral fracture assessment in acromegaly","volume":"16","author":"Madeira","year":"2013","journal-title":"J Clin Densitom"},{"issue":"4","key":"2019041123065755900_B320","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1210\/jc.2012-4073","article-title":"Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography","volume":"98","author":"Madeira","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2019041123065755900_B321","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1210\/jc.2013-2695","article-title":"Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study","volume":"98","author":"Claessen","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041123065755900_B322","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.12262","article-title":"FRAX score in acromegaly: does it tell the whole story","volume":"80","author":"Brzana","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2019041123065755900_B323","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1530\/EJE-14-0205","article-title":"GH receptor isoforms and skeletal fragility in acromegaly","volume":"171","author":"Mormando","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2019041123065755900_B324","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00198-015-3344-2","article-title":"Trabecular bone score as a skeletal fragility index in acromegaly patients","volume":"27","author":"Hong","year":"2016","journal-title":"Osteoporos Int"},{"issue":"2","key":"2019041123065755900_B325","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12020-016-1078-3","article-title":"High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures","volume":"54","author":"Maffezzoni","year":"2016","journal-title":"Endocrine"},{"issue":"2","key":"2019041123065755900_B326","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/EJE-16-0340","article-title":"Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study","volume":"175","author":"Godang","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2019041123065755900_B327","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/EJE-16-0808","article-title":"Bone material strength index as measured by impact microindentation is altered in patients with acromegaly","volume":"176","author":"Malgo","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2019041123065755900_B328","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1530\/EJE-17-0468","article-title":"Bone microarchitecture and estimated bone strength in men with active acromegaly","volume":"177","author":"Silva","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2019041123065755900_B329","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1530\/ERC-17-0253","article-title":"Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge Acromegaly Survey (LAS) Database","volume":"24","author":"Petrossians","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2019041123065755900_B330","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11102-017-0847-1","article-title":"Bone histomorphometry in acromegaly patients with fragility vertebral fractures","volume":"21","author":"Dalle Carbonare","year":"2018","journal-title":"Pituitary"},{"issue":"2","key":"2019041123065755900_B331","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12020-017-1391-5","article-title":"Prevalence of morphometric vertebral fractures in \u201cdifficult\u201d patients with acromegaly with different biochemical outcomes after multimodal treatment","volume":"59","author":"Chiloiro","year":"2018","journal-title":"Endocrine"},{"issue":"3","key":"2019041123065755900_B332","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11102-018-0873-7","article-title":"Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly [published correction appears in Pituitary 2018;21(3):309]","volume":"21","author":"Chiloiro","year":"2018","journal-title":"Pituitary"},{"issue":"5","key":"2019041123065755900_B333","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2213-8587(15)00036-4","article-title":"Growth hormone replacement therapy and fracture risk","volume":"3","author":"Giustina","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2019041123065755900_B334","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/EJE-15-0118","article-title":"Management of endocrine disease: secondary osteoporosis: pathophysiology and management","volume":"173","author":"Mirza","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2019041123065755900_B335","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1210\/jc.2009-1172","article-title":"The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly","volume":"94","author":"Wassenaar","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B336","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000371808","article-title":"The history of acromegaly","volume":"103","author":"de Herder","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2019041123065755900_B337","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11102-011-0310-7","article-title":"Clinical, quality of life, and economic value of acromegaly disease control","volume":"14","author":"Ben-Shlomo","year":"2011","journal-title":"Pituitary"},{"issue":"10","key":"2019041123065755900_B338","doi-asserted-by":"crossref","first-page":"793","DOI":"10.7326\/0003-4819-128-10-199805150-00001","article-title":"The association of radiographically detected vertebral fractures with back pain and function: a prospective study","volume":"128","author":"Nevitt","year":"1998","journal-title":"Ann Intern Med"},{"issue":"7","key":"2019041123065755900_B339","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1359\/jbmr.2000.15.7.1384","article-title":"Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures","volume":"15","author":"Oleksik","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2019041123065755900_B340","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1530\/EJE-12-0566","article-title":"Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure","volume":"167","author":"Mazziotti","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2019041123065755900_B341","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","article-title":"Hyperprolactinemia and prolactinomas","volume":"37","author":"Mancini","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"2019041123065755900_B342","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1359\/jbmr.2000.15.1.129","article-title":"The effect of pregnancy on bone density and bone turnover","volume":"15","author":"Naylor","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2019041123065755900_B343","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1515\/CCLM.1999.071","article-title":"Biomarkers of bone turnover and bone mineral density in hyperprolactinemic amenorrheic women","volume":"37","author":"Shaarawy","year":"1999","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"2019041123065755900_B344","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1365-2265.2000.00902.x","article-title":"Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization","volume":"52","author":"Colao","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2019041123065755900_B345","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1210\/jcem.83.3.4674","article-title":"Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males","volume":"83","author":"Di Somma","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B346","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/BF03345523","article-title":"Prevalence of osteopenia in men with prolactinoma","volume":"28","author":"Naliato","year":"2005","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2019041123065755900_B347","first-page":"692","article-title":"Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea","volume":"75","author":"Biller","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041123065755900_B348","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jama.1984.03340290040017","article-title":"Decreased spinal mineral content in amenorrheic women","volume":"251","author":"Cann","year":"1984","journal-title":"JAMA"},{"issue":"6","key":"2019041123065755900_B349","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1210\/jcem-56-6-1120","article-title":"Bone density in amenorrheic women with and without hyperprolactinemia","volume":"56","author":"Schlechte","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B350","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11102-007-0064-4","article-title":"Bone density in women with prolactinoma treated with dopamine agonists","volume":"11","author":"Naliato","year":"2008","journal-title":"Pituitary"},{"issue":"26","key":"2019041123065755900_B351","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJM198012253032605","article-title":"Decreased bone density in hyperprolactinemic women","volume":"303","author":"Klibanski","year":"1980","journal-title":"N Engl J Med"},{"issue":"1","key":"2019041123065755900_B352","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1210\/jcem-67-1-124","article-title":"Effects of prolactin and estrogen deficiency in amenorrheic bone loss","volume":"67","author":"Klibanski","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2019041123065755900_B353","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-110-7-526","article-title":"Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism","volume":"110","author":"Greenspan","year":"1989","journal-title":"Ann Intern Med"},{"issue":"4","key":"2019041123065755900_B354","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11102-011-0293-4","article-title":"High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas","volume":"14","author":"Mazziotti","year":"2011","journal-title":"Pituitary"},{"issue":"3","key":"2019041123065755900_B355","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12020-011-9462-5","article-title":"Vertebral fractures in males with prolactinoma","volume":"39","author":"Mazziotti","year":"2011","journal-title":"Endocrine"},{"issue":"8","key":"2019041123065755900_B356","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1530\/EC-17-0171","article-title":"Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study","volume":"6","author":"Soto-Pedre","year":"2017","journal-title":"Endocr Connect"},{"key":"2019041123065755900_B357","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000443866","article-title":"Skeletal fragility in endogenous hypercortisolism","volume":"46","author":"Mazziotti","year":"2016","journal-title":"Front Horm Res"},{"issue":"4","key":"2019041123065755900_B358","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11102-005-1051-2","article-title":"Cushing\u2019s syndrome and bone","volume":"7","author":"Mancini","year":"2004","journal-title":"Pituitary"},{"issue":"6","key":"2019041123065755900_B359","first-page":"1863","article-title":"Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing\u2019s syndrome","volume":"83","author":"Chiodini","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B360","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.0300-0664.2001.01454.doc.x","article-title":"Severe impairment of bone mass and turnover in Cushing\u2019s disease: comparison between childhood-onset and adulthood-onset disease","volume":"56","author":"Di Somma","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2019041123065755900_B361","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/eje.1.02067","article-title":"Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing\u2019s syndrome: a prospective, long-term study","volume":"154","author":"Kristo","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2019041123065755900_B362","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2265.2003.01713.x","article-title":"Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing\u2019s disease: a prospective study","volume":"58","author":"Di Somma","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2019041123065755900_B363","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1507\/endocrj.50.1","article-title":"Osteoporosis is more prevalent in adrenal than in pituitary Cushing\u2019s syndrome","volume":"50","author":"Ohmori","year":"2003","journal-title":"Endocr J"},{"issue":"5","key":"2019041123065755900_B364","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1210\/jc.2005-0582","article-title":"Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status","volume":"91","author":"Tauchmanov\u00e0","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B365","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0272","article-title":"The European Registry on Cushing\u2019s syndrome: 2-year experience. Baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2019041123065755900_B366","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00198-013-2520-5","article-title":"Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants","volume":"25","author":"Trementino","year":"2014","journal-title":"Osteoporos Int"},{"issue":"4","key":"2019041123065755900_B367","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/cen.12812","article-title":"Bone density and microarchitecture in endogenous hypercortisolism","volume":"83","author":"dos Santos","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2019041123065755900_B368","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2265.2002.01602.x","article-title":"Bone metabolism and mass in women with Cushing\u2019s syndrome and adrenal incidentaloma","volume":"57","author":"Francucci","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2019041123065755900_B369","first-page":"2859","article-title":"Bone mineral density and bone turnover before and after surgical cure of Cushing\u2019s syndrome","volume":"80","author":"Hermus","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B370","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1530\/eje.0.1410126","article-title":"Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing\u2019s syndrome","volume":"141","author":"Godang","year":"1999","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2019041123065755900_B371","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s001980170025","article-title":"Recovery of bone mineral density after surgical cure, but not by ketoconazole treatment, in Cushing\u2019s syndrome","volume":"12","author":"Luisetto","year":"2001","journal-title":"Osteoporos Int"},{"issue":"11","key":"2019041123065755900_B372","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00198-004-1616-3","article-title":"Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing\u2019s syndrome","volume":"15","author":"Minetto","year":"2004","journal-title":"Osteoporos Int"},{"issue":"4","key":"2019041123065755900_B373","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1210\/jc.2002-021518","article-title":"Gender-related differences in the presentation and course of Cushing\u2019s disease","volume":"88","author":"Pecori Giraldi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B374","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/eje.0.1460051","article-title":"Increased risk of osteoporotic fractures in patients with Cushing\u2019s syndrome","volume":"146","author":"Vestergaard","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2019041123065755900_B375","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1023\/A:1015362822901","article-title":"Spine abnormalities and damage in patients cured from Cushing\u2019s disease","volume":"4","author":"Faggiano","year":"2001","journal-title":"Pituitary"},{"issue":"3","key":"2019041123065755900_B376","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1530\/EJE-07-0137","article-title":"Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism","volume":"157","author":"Tauchmanov\u00e0","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2019041123065755900_B377","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00198-007-0514-x","article-title":"Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing\u2019s syndrome","volume":"19","author":"F\u00fcto","year":"2008","journal-title":"Osteoporos Int"},{"issue":"1","key":"2019041123065755900_B378","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11657-015-0244-1","article-title":"The risk factors for fractures and trabecular bone-score value in patients with endogenous Cushing\u2019s syndrome","volume":"10","author":"Belaya","year":"2015","journal-title":"Arch Osteoporos"},{"issue":"2","key":"2019041123065755900_B379","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","article-title":"High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study","volume":"39","author":"Angeli","year":"2006","journal-title":"Bone"},{"issue":"8","key":"2019041123065755900_B380","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/jbmr.398","article-title":"Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study","volume":"26","author":"Morelli","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2019041123065755900_B381","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s001980170115","article-title":"Oral glucocorticoid-induced fall in cortical bone volume and density in postmenopausal asthmatic patients","volume":"12","author":"Tsugeno","year":"2001","journal-title":"Osteoporos Int"},{"issue":"1","key":"2019041123065755900_B382","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1359\/jbmr.2001.16.1.97","article-title":"Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis","volume":"16","author":"Dalle Carbonare","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2019041123065755900_B383","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1530\/EJE-16-1029","article-title":"Diagnosis of endocrine disease: diagnostic approach to TSH-producing pituitary adenoma","volume":"177","author":"Tj\u00f6rnstrand","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2019041123065755900_B384","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/105072503322238854","article-title":"Hyperthyroidism, bone mineral, and fracture risk\u2014a meta-analysis","volume":"13","author":"Vestergaard","year":"2003","journal-title":"Thyroid"},{"issue":"2","key":"2019041123065755900_B385","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1365-2265.1997.2351057.x","article-title":"Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH","volume":"47","author":"Persani","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2019041123065755900_B386","doi-asserted-by":"crossref","first-page":"e2358","DOI":"10.1097\/MD.0000000000002358","article-title":"Somatostatin analogue treatment of a TSH-secreting adenoma presenting with accelerated bone metabolism and a pericardial effusion: a case report","volume":"95","author":"Mousiolis","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2019041123065755900_B387","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00774-009-0050-1","article-title":"Atypical thyrotropin-secreting pituitary microadenoma revealed by severe osteoporosis in a young man","volume":"27","author":"de Rougemont","year":"2009","journal-title":"J Bone Miner Metab"},{"issue":"10058","key":"2019041123065755900_B388","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/S0140-6736(16)30053-8","article-title":"Hypopituitarism","volume":"388","author":"Higham","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"2019041123065755900_B389","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1210\/jc.2005-0288","article-title":"Primary empty sella","volume":"90","author":"De Marinis","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"9571","key":"2019041123065755900_B390","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(07)60673-4","article-title":"Hypopituitarism","volume":"369","author":"Schneider","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"2019041123065755900_B391","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11102-006-0410-y","article-title":"Growth hormone deficiency in the adult","volume":"9","author":"Doga","year":"2006","journal-title":"Pituitary"},{"issue":"4","key":"2019041123065755900_B392","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jbmr.5650010406","article-title":"Serum bone GLA-protein in growth hormone deficient children","volume":"1","author":"Delmas","year":"1986","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2019041123065755900_B393","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF02555871","article-title":"Serum osteocalcin and bone isoenzyme alkaline phosphatase in growth hormone-deficient patients: dose-response studies with biosynthetic human GH","volume":"48","author":"Nielsen","year":"1991","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"2019041123065755900_B394","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/BF03348952","article-title":"Growth hormone treatment in adults with GH deficiency: effects on new biochemical markers of bone and collagen turnover","volume":"16","author":"Sartorio","year":"1993","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2019041123065755900_B395","first-page":"1462","article-title":"Elderly patients with adult-onset growth hormone deficiency are not osteopenic","volume":"82","author":"Toogood","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B396","first-page":"55","article-title":"Growth hormone and bone","volume":"19","author":"Ohlsson","year":"1998","journal-title":"Endocr Rev"},{"issue":"2","key":"2019041123065755900_B397","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S8756-3282(02)00952-3","article-title":"Parathyroid hormone secretory pattern, circulating activity, and effect on bone turnover in adult growth hormone deficiency","volume":"32","author":"Ahmad","year":"2003","journal-title":"Bone"},{"issue":"6","key":"2019041123065755900_B398","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2265.2006.02667.x","article-title":"Bone mineral density in patients with growth hormone deficiency: does a gender difference exist","volume":"65","author":"Hitz","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2019041123065755900_B399","first-page":"3304","article-title":"Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption","volume":"80","author":"Ledger","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2019041123065755900_B400","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1359\/jbmr.070715","article-title":"PTH circadian rhythm and PTH target-organ sensitivity is altered in patients with adult growth hormone deficiency with low BMD","volume":"22","author":"White","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2019041123065755900_B401","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1210\/jc.2011-0179","article-title":"Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Molitch","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041123065755900_B402","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2796.1992.tb00613.x","article-title":"The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I","volume":"232","author":"Johansson","year":"1992","journal-title":"J Intern Med"},{"key":"2019041123065755900_B403","first-page":"41","article-title":"Preliminary study of the effects of growth hormone substitution therapy on bone mineral density and serum osteocalcin levels in adults with growth hormone deficiency","volume":"128","author":"Thor\u00e9n","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"3","key":"2019041123065755900_B404","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00298715","article-title":"Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3","volume":"52","author":"Bing-You","year":"1993","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2019041123065755900_B405","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1530\/acta.0.1290201","article-title":"Reduced bone mineral content in adult patients with growth hormone deficiency","volume":"129","author":"Ros\u00e9n","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"3","key":"2019041123065755900_B406","first-page":"669","article-title":"Reduced bone mineral density in patients with adult onset growth hormone deficiency","volume":"78","author":"Holmes","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B407","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2265.1995.tb01860.x","article-title":"Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults","volume":"42","author":"Beshyah","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2019041123065755900_B408","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1530\/eje.0.1330180","article-title":"Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy","volume":"133","author":"Degerblad","year":"1995","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2019041123065755900_B409","first-page":"2865","article-title":"Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency","volume":"81","author":"Johannsson","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041123065755900_B410","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1365-2265.1998.00439.x","article-title":"Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults","volume":"48","author":"Kann","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2019041123065755900_B411","first-page":"4104","article-title":"Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease","volume":"85","author":"Fernholm","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B412","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2265.2002.01582.x","article-title":"Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies","volume":"57","author":"Abrahamsen","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2019041123065755900_B413","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1210\/jc.2003-030685","article-title":"Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly","volume":"89","author":"Murray","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041123065755900_B414","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1210\/jc.2003-030346","article-title":"Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Hoffman","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B415","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1365-2265.2005.02343.x","article-title":"Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men","volume":"63","author":"Arwert","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2019041123065755900_B416","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1172\/JCI117034","article-title":"Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model","volume":"93","author":"Matkovic","year":"1994","journal-title":"J Clin Invest"},{"issue":"6","key":"2019041123065755900_B417","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s001980050173","article-title":"Evolution of lumbar bone mineral content during adolescence and adulthood: a longitudinal study in 395 healthy females 10\u201324 years of age and 206 premenopausal women","volume":"9","author":"Sabatier","year":"1999","journal-title":"Osteoporos Int"},{"key":"2019041123065755900_B418","first-page":"985","article-title":"Peak bone mass","volume":"4","author":"Heaney","year":"2000","journal-title":"Osteoporos Int"},{"issue":"6","key":"2019041123065755900_B419","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1359\/jbmr.2002.17.6.1081","article-title":"The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial","volume":"17","author":"Bex","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2019041123065755900_B420","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2265.2003.01949.x","article-title":"Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD","volume":"60","author":"Baroncelli","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2019041123065755900_B421","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1210\/jc.2005-0208","article-title":"Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial","volume":"90","author":"Mauras","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041123065755900_B422","first-page":"82","article-title":"Transition of childhood-onset growth hormone-deficient patients to adult healthcare","volume":"4","author":"Rapaport","year":"2006","journal-title":"Pediatr Endocrinol Rev"},{"issue":"4","key":"2019041123065755900_B423","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1210\/jc.2007-0167","article-title":"Approach to the growth hormone-deficient child during transition to adulthood","volume":"92","author":"Radovick","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B424","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2265.2009.03686.x","article-title":"Childhood growth hormone deficiency, bone density, structures and fractures: scrutinizing the evidence","volume":"72","author":"H\u00f6gler","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2019041123065755900_B425","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1210\/jc.2004-0054","article-title":"Bone status and fracture prevalence in Russian adults with childhood-onset growth hormone deficiency","volume":"89","author":"Bouillon","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2019041123065755900_B426","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/jbmr.5650090822","article-title":"Consequences of childhood-onset growth hormone deficiency for adult bone mass","volume":"9","author":"de Boer","year":"1994","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2019041123065755900_B427","first-page":"1344","article-title":"Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency","volume":"76","author":"O\u2019Halloran","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B428","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2005-0897","article-title":"A densitometric and morphometric analysis of the skeleton in adults with varying degrees of growth hormone deficiency","volume":"91","author":"Murray","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019041123065755900_B429","first-page":"1919","article-title":"Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019041123065755900_B430","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1530\/EJE-07-0384","article-title":"Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults","volume":"157","author":"Corneli","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2019041123065755900_B431","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tem.2014.10.005","article-title":"Growth hormone deficiency in treated acromegaly","volume":"26","author":"Mazziotti","year":"2015","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B432","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.beem.2017.03.002","article-title":"Growth hormone deficiency in treated acromegaly and active Cushing\u2019s syndrome","volume":"31","author":"Formenti","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B433","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/eje.0.1460067","article-title":"Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing\u2019s disease","volume":"146","author":"Feldt-Rasmussen","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2019041123065755900_B434","first-page":"118","article-title":"Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset","volume":"74","author":"Kaufman","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B435","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1359\/jbmr.2001.16.2.398","article-title":"The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density","volume":"16","author":"W\u00fcster","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2019041123065755900_B436","doi-asserted-by":"crossref","first-page":"E1710","DOI":"10.1210\/jc.2013-2349","article-title":"Isolated GH deficiency due to a GHRH receptor mutation causes hip joint problems and genu valgum, and reduces size but not density of trabecular and mixed bone","volume":"98","author":"Epit\u00e1cio-Pereira","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019041123065755900_B437","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/8756-3282(96)00069-5","article-title":"Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men","volume":"18","author":"Bravenboer","year":"1996","journal-title":"Bone"},{"issue":"3","key":"2019041123065755900_B438","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1530\/eje.0.1370240","article-title":"Increased fracture frequency in adult patients with hypopituitarism and GH deficiency","volume":"137","author":"Ros\u00e9n","year":"1997","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2019041123065755900_B439","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1359\/JBMR.050613","article-title":"Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men","volume":"20","author":"Bravenboer","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2019041123065755900_B440","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1359\/jbmr.060112","article-title":"Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy","volume":"21","author":"Mazziotti","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2019041123065755900_B441","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1359\/jbmr.070811","article-title":"Fracture incidence in GH-deficient patients on complete hormone replacement including GH","volume":"22","author":"Holmer","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019041123065755900_B442","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11102-007-0069-z","article-title":"Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency","volume":"11","author":"Mazziotti","year":"2008","journal-title":"Pituitary"},{"issue":"1","key":"2019041123065755900_B443","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/EJE-10-0125","article-title":"Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency","volume":"163","author":"Mazziotti","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2019041123065755900_B444","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1210\/jc.2010-2662","article-title":"Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database analysis","volume":"96","author":"Tritos","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041123065755900_B445","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1530\/EJE-11-1072","article-title":"Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency","volume":"166","author":"Elbornsson","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2019041123065755900_B446","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ghir.2013.12.001","article-title":"Impact of the growth hormone replacement on bone status in growth hormone deficient adults","volume":"24","author":"Kuzma","year":"2014","journal-title":"Growth Horm IGF Res"},{"issue":"6","key":"2019041123065755900_B447","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1530\/EJE-14-0097","article-title":"Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism","volume":"170","author":"Mazziotti","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2019041123065755900_B448","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S2213-8587(15)00098-4","article-title":"Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study","volume":"3","author":"Mo","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2019041123065755900_B449","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/2042018816643908","article-title":"Seven years of follow up of trabecular bone score, bone mineral density, body composition and quality of life in adults with growth hormone deficiency treated with rhGH replacement in a single center","volume":"7","author":"Allo Miguel","year":"2016","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B450","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12020-015-0738-z","article-title":"Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency","volume":"52","author":"Mazziotti","year":"2016","journal-title":"Endocrine"},{"issue":"5","key":"2019041123065755900_B451","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/cen.13161","article-title":"Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients","volume":"85","author":"Mormando","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2019041123065755900_B452","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11102-016-0716-3","article-title":"Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults","volume":"19","author":"van Varsseveld","year":"2016","journal-title":"Pituitary"},{"issue":"3","key":"2019041123065755900_B453","first-page":"970","article-title":"Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency","volume":"85","author":"Biller","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B454","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ecl.2014.10.009","article-title":"Efficacy and complications of pituitary irradiation","volume":"44","author":"Ntali","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"2019041123065755900_B455","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2265.2010.03815.x","article-title":"The interaction between growth hormone and the thyroid axis in hypopituitary patients","volume":"74","author":"Behan","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2019041123065755900_B456","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1210\/jc.2012-1616","article-title":"Clinical review: central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges","volume":"97","author":"Persani","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2019041123065755900_B457","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"2019041123065755900_B458","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1001\/jama.294.19.2481","article-title":"Adrenal insufficiency","volume":"294","author":"Salvatori","year":"2005","journal-title":"JAMA"},{"issue":"4","key":"2019041123065755900_B459","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2265.2010.03838.x","article-title":"Morbidity and mortality in patients with craniopharyngioma after surgery","volume":"73","author":"Crowley","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2019041123065755900_B460","doi-asserted-by":"crossref","first-page":"354","DOI":"10.7326\/0003-4819-106-3-","article-title":"Osteoporosis in men with idiopathic hypogonadotropic hypogonadism","volume":"106","author":"Finkelstein","year":"1987","journal-title":"Ann Intern Med"},{"issue":"6","key":"2019041123065755900_B461","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3346\/jkms.1995.10.6.431","article-title":"Site-specific effect of testosterone on bone mineral density in male hypogonadism","volume":"10","author":"Choi","year":"1995","journal-title":"J Korean Med Sci"},{"issue":"4","key":"2019041123065755900_B462","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/BF03343854","article-title":"Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic hypogonadal men after prolonged testosterone treatment","volume":"24","author":"De Rosa","year":"2001","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2019041123065755900_B463","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2605.2011.01237.x","article-title":"Bone mineral density, body composition and bone turnover in patients with congenital hypogonadotropic hypogonadism","volume":"35","author":"Laitinen","year":"2012","journal-title":"Int J Androl"},{"key":"2019041123065755900_B464","doi-asserted-by":"crossref","first-page":"324524","DOI":"10.1155\/2015\/324524","article-title":"Changes in bone mineral density and metabolic parameters after pulsatile gonadorelin treatment in young men with hypogonadotropic hypogonadism","volume":"2015","author":"Li","year":"2015","journal-title":"Int J Endocrinol"},{"key":"2019041123065755900_B465","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1007\/s40520-015-0421-5","article-title":"Bone involvement in males with Kallmann disease","volume":"27","author":"Iolascon","year":"2015","journal-title":"Aging Clin Exp Res"},{"key":"2019041123065755900_B466","doi-asserted-by":"crossref","first-page":"4602129","DOI":"10.1155\/2017\/4602129","article-title":"Male hypogonadism and osteoporosis: the effects, clinical consequences, and treatment of testosterone deficiency in bone health","volume":"2017","author":"Golds","year":"2017","journal-title":"Int J Endocrinol"},{"issue":"8","key":"2019041123065755900_B467","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1210\/jcem.82.8.4163","article-title":"Long-term effect of testosterone therapy on bone mineral density in hypogonadal men","volume":"82","author":"Behre","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B468","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12020-014-0278-y","article-title":"Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect","volume":"47","author":"Giustina","year":"2014","journal-title":"Endocrine"},{"issue":"1","key":"2019041123065755900_B469","first-page":"122","article-title":"Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone","volume":"80","author":"Giustina","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B470","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bone.2005.07.002","article-title":"Bone ultrasonometric features and growth hormone secretion in asthmatic patients during chronic inhaled corticosteroid therapy","volume":"38","author":"Malerba","year":"2006","journal-title":"Bone"},{"issue":"40","key":"2019041123065755900_B471","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"issue":"11","key":"2019041123065755900_B472","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1359\/jbmr.2003.18.11.1947","article-title":"BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures","volume":"18","author":"Stone","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019041123065755900_B473","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","article-title":"Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study","volume":"34","author":"Schuit","year":"2004","journal-title":"Bone"},{"issue":"1","key":"2019041123065755900_B474","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12020-011-9570-2","article-title":"New understanding and treatments for osteoporosis","volume":"41","author":"Mazziotti","year":"2012","journal-title":"Endocrine"},{"issue":"10","key":"2019041123065755900_B475","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40618-014-0126-1","article-title":"Fracture risk assessment before and after resolution of endogenous hypercortisolism: is the FRAX\u00ae algorithm useful","volume":"37","author":"Trementino","year":"2014","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"2019041123065755900_B476","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-207907","article-title":"The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis","volume":"74","author":"Marques","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2019041123065755900_B477","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00198-006-0199-6","article-title":"Severity of vertebral fracture reflects deterioration of bone microarchitecture","volume":"18","author":"Genant","year":"2007","journal-title":"Osteoporos Int"},{"issue":"3","key":"2019041123065755900_B478","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00198-004-1691-5","article-title":"Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis","volume":"16","author":"Lindsay","year":"2005","journal-title":"Osteoporos Int"},{"issue":"1","key":"2019041123065755900_B479","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00198-013-2460-0","article-title":"Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures","volume":"25","author":"Johansson","year":"2014","journal-title":"Osteoporos Int"},{"issue":"10","key":"2019041123065755900_B480","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/jbmr.1648","article-title":"Bone quality, as measured by trabecular bone score in patients with adrenal incidentalomas with and without subclinical hypercortisolism","volume":"27","author":"Eller-Vainicher","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2019041123065755900_B481","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/TCRM.S12952","article-title":"Treatment of Cushing disease: overview and recent findings","volume":"6","author":"Mancini","year":"2010","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"2019041123065755900_B482","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/BF03349263","article-title":"Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults","volume":"31","author":"Giustina","year":"2008","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2019041123065755900_B483","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"Melmed","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B484","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000351007","article-title":"2013 European Thyroid Association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors","volume":"2","author":"Beck-Peccoz","year":"2013","journal-title":"Eur Thyroid J"},{"issue":"5","key":"2019041123065755900_B485","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","article-title":"Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a Pituitary Society statement","volume":"20","author":"Casanueva","year":"2017","journal-title":"Pituitary"},{"issue":"8","key":"2019041123065755900_B486","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/jnnp-2012-303194","article-title":"Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis","volume":"84","author":"Ammirati","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2019041123065755900_B487","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"2019041123065755900_B488","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2019041123065755900_B489","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12020-014-0281-3","article-title":"Surgical treatment of microprolactinomas: pros","volume":"47","author":"Salvatori","year":"2014","journal-title":"Endocrine"},{"issue":"2","key":"2019041123065755900_B490","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B491","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11102-010-0269-9","article-title":"Current management practices for acromegaly: an international survey","volume":"14","author":"Giustina","year":"2011","journal-title":"Pituitary"},{"issue":"4","key":"2019041123065755900_B492","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"2019041123065755900_B493","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1210\/jc.2008-0027","article-title":"A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly","volume":"93","author":"Murray","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B494","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s11102-014-0570-0","article-title":"Octreotide LAR treatment of acromegaly in \u201creal life\u201d: long-term outcome at a tertiary care center","volume":"18","author":"Espinosa-de-los-Monteros","year":"2015","journal-title":"Pituitary"},{"issue":"2","key":"2019041123065755900_B495","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-09-0372","article-title":"High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial","volume":"161","author":"Giustina","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2019041123065755900_B496","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2017-00142","article-title":"High-dose and high-frequency lanreotide Autogel in acromegaly: a randomized, multicenter study","volume":"102","author":"Giustina","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B497","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11102-009-0169-z","article-title":"Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review","volume":"13","author":"Mazziotti","year":"2010","journal-title":"Pituitary"},{"issue":"5","key":"2019041123065755900_B498","doi-asserted-by":"crossref","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One"},{"key":"2019041123065755900_B499","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.pmbts.2015.10.015","article-title":"The modern criteria for medical management of acromegaly","volume":"138","author":"Frara","year":"2016","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"6","key":"2019041123065755900_B500","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40618-017-0614-1","article-title":"Pegvisomant in acromegaly: an update [published correction appears in J Endocrinol Invest 2018;42(2)267]","volume":"40","author":"Giustina","year":"2017","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2019041123065755900_B501","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/BF03349183","article-title":"Resistance to somatostatin analogs in acromegaly: an evolving concept","volume":"29","author":"Gola","year":"2006","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2019041123065755900_B502","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1210\/er.2001-0022","article-title":"Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly","volume":"23","author":"Kopchick","year":"2002","journal-title":"Endocr Rev"},{"issue":"1","key":"2019041123065755900_B503","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12020-014-0393-9","article-title":"ACROSTUDY: the Italian experience","volume":"48","author":"Grottoli","year":"2015","journal-title":"Endocrine"},{"issue":"1","key":"2019041123065755900_B504","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11102-012-0382-z","article-title":"Pegvisomant and cabergoline combination therapy in acromegaly","volume":"16","author":"Bernabeu","year":"2013","journal-title":"Pituitary"},{"issue":"2","key":"2019041123065755900_B505","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12020-015-0810-8","article-title":"Combined treatment of somatostatin analogues with pegvisomant in acromegaly","volume":"52","author":"Franck","year":"2016","journal-title":"Endocrine"},{"issue":"11","key":"2019041123065755900_B506","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2019041123065755900_B507","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12020-012-9846-1","article-title":"Mifepristone: is there a place in the treatment of Cushing\u2019s disease","volume":"44","author":"Carmichael","year":"2013","journal-title":"Endocrine"},{"issue":"2","key":"2019041123065755900_B508","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12020-013-0098-5","article-title":"Molecular basis of pharmacological therapy in Cushing\u2019s disease","volume":"46","author":"Ferone","year":"2014","journal-title":"Endocrine"},{"issue":"6","key":"2019041123065755900_B509","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11102-016-0742-1","article-title":"Updates on the role of adrenal steroidogenesis inhibitors in Cushing\u2019s syndrome: a focus on novel therapies","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"1","key":"2019041123065755900_B510","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial","volume":"94","author":"Boscaro","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2019041123065755900_B511","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2019041123065755900_B512","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B513","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12020-016-0863-3","article-title":"Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management","volume":"52","author":"Amlashi","year":"2016","journal-title":"Endocrine"},{"issue":"8","key":"2019041123065755900_B514","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing\u2019s syndrome: an Endocrine Society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041123065755900_B515","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jns.2016.11.024","article-title":"Safety and efficacy of fractionated stereotactic radiotherapy and stereotactic radiosurgery for treatment of pituitary adenomas: A systematic review and meta-analysis","volume":"372","author":"Li","year":"2017","journal-title":"J Neurol Sci"},{"issue":"3","key":"2019041123065755900_B516","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jocd.2007.03.103","article-title":"Bone properties in patients with acromegaly: quantitative ultrasound of the heel","volume":"10","author":"Kastelan","year":"2007","journal-title":"J Clin Densitom"},{"issue":"6","key":"2019041123065755900_B517","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1046\/j.1365-2265.2003.01777.x","article-title":"Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status","volume":"58","author":"Scillitani","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2019041123065755900_B518","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s00198-009-1165-x","article-title":"Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly","volume":"21","author":"Madeira","year":"2010","journal-title":"Osteoporos Int"},{"issue":"1","key":"2019041123065755900_B519","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11102-007-0062-6","article-title":"The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly","volume":"11","author":"De Marinis","year":"2008","journal-title":"Pituitary"},{"issue":"9","key":"2019041123065755900_B520","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJM198608283150903","article-title":"Increase in bone mass after treatment of hyperprolactinemic amenorrhea","volume":"315","author":"Klibanski","year":"1986","journal-title":"N Engl J Med"},{"issue":"5","key":"2019041123065755900_B521","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1210\/jcem-64-5-1021","article-title":"Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea","volume":"64","author":"Schlechte","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019041123065755900_B522","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-104-6-777","article-title":"Osteoporosis in men with hyperprolactinemic hypogonadism","volume":"104","author":"Greenspan","year":"1986","journal-title":"Ann Intern Med"},{"issue":"3","key":"2019041123065755900_B523","first-page":"690","article-title":"Hyperprolactinemia and osteopenia","volume":"75","author":"Wardlaw","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2019041123065755900_B524","first-page":"745","article-title":"Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: a systematic review and meta-analysis","volume":"36","author":"D\u2019Sylva","year":"2015","journal-title":"Neuroendocrinol Lett"},{"issue":"1","key":"2019041123065755900_B525","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1359\/jbmr.061010","article-title":"Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood","volume":"22","author":"Leong","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019041123065755900_B526","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2265.1992.tb01437.x","article-title":"Normal bone mineral density following cure of Cushing\u2019s syndrome","volume":"36","author":"Manning","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2019041123065755900_B527","first-page":"2475","article-title":"Long term follow-up of transsphenoidal surgery for the treatment of Cushing\u2019s disease in childhood","volume":"80","author":"Leinung","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B528","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11102-011-0306-3","article-title":"Spontaneous recovery of bone mass after cure of endogenous hypercortisolism","volume":"15","author":"Randazzo","year":"2012","journal-title":"Pituitary"},{"issue":"3","key":"2019041123065755900_B529","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF03345378","article-title":"Bone mineral density at diagnosis and following successful treatment of pediatric Cushing\u2019s disease","volume":"28","author":"Scommegna","year":"2005","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2019041123065755900_B530","first-page":"1905","article-title":"The effect of Cushing\u2019s disease on bone mineral density, body composition, growth, and puberty: a report of an identical adolescent twin pair","volume":"81","author":"Leong","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2019041123065755900_B531","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1359\/jbmr.2001.16.10.1879","article-title":"Glucocorticoid excess during adolescence leads to a major persistent deficit in bone mass and an increase in central body fat","volume":"16","author":"Abad","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2019041123065755900_B532","doi-asserted-by":"crossref","unstructured":"Scillitani A , MazziottiG, Di SommaC, MorettiS, StiglianoA, PivonelloR, GiustinaA, ColaoA. Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int. 2014;25(2):441\u2013446.","DOI":"10.1007\/s00198-013-2588-y"},{"issue":"9","key":"2019041123065755900_B533","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/jbmr.5650070909","article-title":"Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss","volume":"7","author":"Lukert","year":"1992","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2019041123065755900_B534","doi-asserted-by":"crossref","first-page":"961","DOI":"10.7326\/0003-4819-125-12-199612150-00004","article-title":"Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial","volume":"125","author":"Buckley","year":"1996","journal-title":"Ann Intern Med"},{"issue":"7","key":"2019041123065755900_B535","first-page":"53","article-title":"Prevention and treatment of glucocorticoid-induced osteoporosis","volume":"31","author":"Doga","year":"2008","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2019041123065755900_B536","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/cen.13267","article-title":"Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity\u2014data from the EU-AIR","volume":"86","author":"Murray","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2019041123065755900_B537","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"2019041123065755900_B538","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jc.2009-2631","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline","volume":"95","author":"Speiser","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B539","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041123065755900_B540","doi-asserted-by":"crossref","first-page":"R231","DOI":"10.1530\/EJE-17-0154","article-title":"Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects","volume":"177","author":"Mazziotti","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2019041123065755900_B541","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1365-2265.1998.3641180.x","article-title":"The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11\u03b2-hydroxysteroid dehydrogenase activity","volume":"48","author":"Gelding","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2019041123065755900_B542","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2265.2007.02784.x","article-title":"The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol","volume":"66","author":"Qureshi","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2019041123065755900_B543","first-page":"924","article-title":"Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism","volume":"84","author":"Ferretti","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2019041123065755900_B544","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1089\/105072502760339406","article-title":"Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism","volume":"12","author":"Shimon","year":"2002","journal-title":"Thyroid"},{"issue":"1","key":"2019041123065755900_B545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/eje.0.1500001","article-title":"Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients","volume":"150","author":"Alexopoulou","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2019041123065755900_B546","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11102-011-0356-6","article-title":"The metabolic consequences of thyroxine replacement in adult hypopituitary patients","volume":"15","author":"Filipsson Nystr\u00f6m","year":"2012","journal-title":"Pituitary"},{"issue":"9","key":"2019041123065755900_B547","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1210\/jc.2013-1610","article-title":"Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients","volume":"98","author":"Klose","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B548","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12020-017-1492-1","article-title":"Treatment of adult growth hormone deficiency with human recombinant growth hormone: an update on current evidence and critical review of advantages and pitfalls","volume":"60","author":"Ramos-Lev\u00ed","year":"2018","journal-title":"Endocrine"},{"issue":"9","key":"2019041123065755900_B549","first-page":"3352","article-title":"Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study","volume":"81","author":"Hansen","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041123065755900_B550","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S8756-3282(03)00240-0","article-title":"Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency\u2014relationship with bone turn-over","volume":"33","author":"Ueland","year":"2003","journal-title":"Bone"},{"issue":"10","key":"2019041123065755900_B551","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1210\/jcem.86.10.7887","article-title":"A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices","volume":"86","author":"G\u00f6therstr\u00f6m","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041123065755900_B552","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2265.2001.01246.x","article-title":"The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study","volume":"54","author":"Drake","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2019041123065755900_B553","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/eje.0.1460187","article-title":"Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults\u2014an 18-month randomised, placebo-controlled, double blinded trial","volume":"146","author":"Sneppen","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2019041123065755900_B554","first-page":"2143","article-title":"Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency","volume":"83","author":"Janssen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B555","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1530\/acta.0.1240278","article-title":"Type I and III procollagen propeptides in growth hormone-deficient patients: effects of increasing doses of GH","volume":"124","author":"Jensen","year":"1991","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"10","key":"2019041123065755900_B556","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1210\/jcem.85.10.6881","article-title":"Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections","volume":"85","author":"Amato","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B557","first-page":"1222","article-title":"Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults","volume":"86","author":"Laursen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B558","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-3476(05)83484-5","article-title":"Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency","volume":"122","author":"Saggese","year":"1993","journal-title":"J Pediatr"},{"issue":"3","key":"2019041123065755900_B559","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2265.1994.tb03936.x","article-title":"The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism","volume":"40","author":"Beshyah","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2019041123065755900_B560","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2265.1995.tb01872.x","article-title":"The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults","volume":"42","author":"Beshyah","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041123065755900_B561","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000063448","article-title":"Effects of growth hormone replacement therapy on bone markers and bone mineral density in growth hormone-deficient adults","volume":"54","author":"Nilsson","year":"2000","journal-title":"Horm Res"},{"issue":"6","key":"2019041123065755900_B562","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1210\/jcem-56-6-1246","article-title":"Effects of growth hormone replacement therapy on 1,25-dihydroxyvitamin D and calcium metabolism","volume":"56","author":"Burstein","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041123065755900_B563","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000182189","article-title":"Growth hormone and bone","volume":"36","author":"Bouillon","year":"1991","journal-title":"Horm Res"},{"issue":"1","key":"2019041123065755900_B564","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/eje.0.1360045","article-title":"Growth hormone increases serum 1,25-dihydroxyvitamin D levels and decreases 24,25-dihydroxyvitamin D levels in children with growth hormone deficiency","volume":"136","author":"Wei","year":"1997","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2019041123065755900_B565","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1210\/jc.2002-021787","article-title":"Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism","volume":"88","author":"Ahmad","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B566","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1210\/jc.2014-2912","article-title":"Increased serum and bone matrix levels of the secreted Wnt antagonist DKK-1 in patients with growth hormone deficiency in response to growth hormone treatment","volume":"100","author":"Ueland","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B567","first-page":"107","article-title":"The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults","volume":"83","author":"Cuneo","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041123065755900_B568","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1530\/eje.0.1360282","article-title":"Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up","volume":"136","author":"Finkenstedt","year":"1997","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2019041123065755900_B569","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s002239900392","article-title":"Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency","volume":"62","author":"Kotzmann","year":"1998","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"2019041123065755900_B570","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1365-2265.1998.00405.x","article-title":"Serum collagen crosslinks as markers of bone turn-over during GH replacement therapy in growth hormone deficient adults","volume":"48","author":"Rodr\u00edguez-Arnao","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2019041123065755900_B571","first-page":"2002","article-title":"Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency","volume":"84","author":"Johansson","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041123065755900_B572","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1359\/jbmr.070205","article-title":"Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency","volume":"22","author":"Snyder","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2019041123065755900_B573","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/cen.12493","article-title":"Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study","volume":"81","author":"Appelman-Dijkstra","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2019041123065755900_B574","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2013-3921","article-title":"Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis","volume":"99","author":"Barake","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041123065755900_B575","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2265.1995.tb02591.x","article-title":"Further increase in forearm cortical bone mineral content after discontinuation of growth hormone replacement","volume":"42","author":"Holmes","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2019041123065755900_B576","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/EJE-15-1086","article-title":"Effects of discontinuation of growth hormone replacement in adult GH-deficient patients: a cohort study and a systematic review of the literature","volume":"174","author":"Appelman-Dijkstra","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2019041123065755900_B577","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1530\/EJE-12-0070","article-title":"A longer interval without GH replacement and female gender are associated with lower bone mineral density in adults with childhood-onset GH deficiency: a KIMS database analysis","volume":"167","author":"Tritos","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2019041123065755900_B578","first-page":"327","article-title":"Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency","volume":"16","author":"Baroncelli","year":"2003","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B579","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/cen.12132","article-title":"Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency\u2014a KIMS database analysis","volume":"79","author":"Tritos","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2019041123065755900_B580","doi-asserted-by":"crossref","first-page":"883","DOI":"10.7326\/0003-4819-125-11-199612010-00003","article-title":"Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial","volume":"125","author":"Baum","year":"1996","journal-title":"Ann Intern Med"},{"issue":"4","key":"2019041123065755900_B581","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00223-010-9459-8","article-title":"Predictors of bone responsiveness to growth hormone (GH) replacement in adult GH-deficient patients","volume":"88","author":"Rossini","year":"2011","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2019041123065755900_B582","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/BF03345574","article-title":"Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender","volume":"31","author":"Rota","year":"2008","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2019041123065755900_B583","first-page":"1369","article-title":"Effects of sex and age on the growth hormone response to galanin in healthy human subjects","volume":"76","author":"Giustina","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041123065755900_B584","first-page":"1210","article-title":"Maturation of the regulation of growth hormone secretion in young males with hypogonadotropic hypogonadism pharmacologically exposed to progressive increments in serum testosterone","volume":"82","author":"Giustina","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019041123065755900_B585","first-page":"257","article-title":"Growth hormone deficiency and replacement in patients with treated Cushing\u2019s disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density","volume":"66","author":"Colson","year":"2006","journal-title":"Horm Res"},{"issue":"1","key":"2019041123065755900_B586","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12020-017-1440-0","article-title":"Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis","volume":"59","author":"Barake","year":"2018","journal-title":"Endocrine"},{"issue":"12","key":"2019041123065755900_B587","first-page":"4358","article-title":"Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism","volume":"81","author":"Katznelson","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2019041123065755900_B588","first-page":"2670","article-title":"Effects of testosterone replacement in hypogonadal men","volume":"85","author":"Snyder","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2019041123065755900_B589","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1359\/JBMR.050606","article-title":"Effect of testosterone replacement on trabecular architecture in hypogonadal men","volume":"20","author":"Benito","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2019041123065755900_B590","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1359\/jbmr.080405","article-title":"In vivo microMRI-based finite element and morphological analyses of tibial trabecular bone in eugonadal and hypogonadal men before and after testosterone treatment","volume":"23","author":"Zhang","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019041123065755900_B591","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s12020-016-0882-0","article-title":"Treatment of hypothyroidism: all that glitters is gold","volume":"52","author":"Formenti","year":"2016","journal-title":"Endocrine"},{"issue":"6","key":"2019041123065755900_B592","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1530\/eje.0.1330646","article-title":"Influence of thyroid hormones on the regulation of growth hormone secretion","volume":"133","author":"Giustina","year":"1995","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2019041123065755900_B593","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1210\/jc.2007-0941","article-title":"Growth hormone replacement improves thyroxine biological effects: implications for management of central hypothyroidism","volume":"92","author":"Martins","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B594","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2265.2011.04174.x","article-title":"Glucocorticoid replacement therapy is independently associated with reduced bone mineral density in women with hypopituitarism","volume":"76","author":"Ragnarsson","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2019041123065755900_B595","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1210\/jc.2013-3851","article-title":"The impact of glucocorticoid replacement on bone mineral density in patients with hypopituitarism before and after 2 years of growth hormone replacement therapy","volume":"99","author":"Ragnar Agnarsson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019041123065755900_B596","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1046\/j.1365-2265.1999.00787.x","article-title":"Optimization of glucocorticoid replacement therapy: the long-term effect on bone mineral density","volume":"50","author":"Peacey","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2019041123065755900_B597","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12020-017-1512-1","article-title":"Bone safety of dual-release hydrocortisone in patients with hypopituitarism","volume":"60","author":"Frara","year":"2018","journal-title":"Endocrine"},{"issue":"10","key":"2019041123065755900_B598","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.amjmed.2010.02.028","article-title":"Drug-induced osteoporosis: mechanisms and clinical implications","volume":"123","author":"Mazziotti","year":"2010","journal-title":"Am J Med"},{"issue":"2","key":"2019041123065755900_B599","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor \u03baB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"issue":"8","key":"2019041123065755900_B600","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"2019041123065755900_B601","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1210\/jc.2014-4079","article-title":"A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial","volume":"100","author":"Langdahl","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2019041123065755900_B602","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"issue":"9992","key":"2019041123065755900_B603","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"2019041123065755900_B604","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1210\/er.2001-4002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"issue":"11","key":"2019041123065755900_B605","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"2019041123065755900_B606","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev"},{"issue":"19","key":"2019041123065755900_B607","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"20","key":"2019041123065755900_B608","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"2019041123065755900_B609","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2265.1995.tb02038.x","article-title":"Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH-deficient adults: the effects on renal phosphate handling, bone turnover and bone mineral mass","volume":"43","author":"Valk","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2019041123065755900_B610","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1046\/j.1365-2265.1998.00486.x","article-title":"Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing\u2019s disease","volume":"48","author":"Di Somma","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2019041123065755900_B611","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1210\/jcem.86.7.7669","article-title":"Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial","volume":"86","author":"Biermasz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041123065755900_B612","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2265.2004.02021.x","article-title":"Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study","volume":"60","author":"Biermasz","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2019041123065755900_B613","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/jc.2010-1929","article-title":"Effect of oral phosphate and alendronate on bone mineral density when given as adjunctive therapy to growth hormone replacement in adult growth hormone deficiency","volume":"96","author":"White","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041123065755900_B614","doi-asserted-by":"crossref","first-page":"153","DOI":"10.11005\/jbm.2012.19.2.153","article-title":"A case of Cushing syndrome diagnosed by recurrent pathologic fractures in a young woman","volume":"19","author":"Han","year":"2012","journal-title":"J Bone Metab"},{"key":"2019041123065755900_B615","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bonr.2015.03.001","article-title":"Insights on accelerated skeletal repair in Cushing\u2019s disease","volume":"2","author":"Kim","year":"2015","journal-title":"Bone Rep"},{"issue":"2","key":"2019041123065755900_B616","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12020-016-1118-z","article-title":"Estrogens and selective estrogen receptor modulators in acromegaly","volume":"54","author":"Duarte","year":"2016","journal-title":"Endocrine"},{"issue":"3","key":"2019041123065755900_B617","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/ERC-17-0523","article-title":"Runx2 overexpression compromises bone quality in acromegalic patients","volume":"25","author":"Valenti","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2019041123065755900_B618","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: mechanisms of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"issue":"8","key":"2019041123065755900_B619","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.23279","article-title":"2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2019041123065755900_B620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J Bone Oncol"},{"issue":"1","key":"2019041123065755900_B621","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-016-3716-2","article-title":"Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus","volume":"28","author":"Khan","year":"2017","journal-title":"Osteoporos Int"},{"issue":"7","key":"2019041123065755900_B622","first-page":"16","article-title":"Glucocorticoid-induced osteoporosis and parathyroid hormone","volume":"33","author":"Carpinteri","year":"2010","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2019041123065755900_B623","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2265.1994.tb03788.x","article-title":"The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients","volume":"41","author":"Juul","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2019041123065755900_B624","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00198-017-4241-7","article-title":"Effects of endogenous hypercortisolism on bone mRNA and microRNA expression in humans","volume":"29","author":"Belaya","year":"2018","journal-title":"Osteoporos Int"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/39\/4\/440\/25542241\/er.2018-00005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T04:57:15Z","timestamp":1720241835000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/39\/4\/440\/4975444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,19]]},"references-count":624,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,19]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/er.2018-00005","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,4,19]]}}}